,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,422,1,5,,17404738,446727,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
1,429,1,5,,17404738,446727,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
2,429,1,5,,17404738,446727,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
3,436,2,1,,17404738,446727,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
4,547,1,4,,17404738,446727,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
5,694,1,1,,17404738,446727,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
6,732,1,2,,17404738,446727,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
7,880,2,1,,50105913,446727,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
8,880,2,1,,50105913,446727,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
9,894,2,1,,50105913,446727,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
10,940,1,2,,17404738,446727,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
11,1030,2,1,,50105913,446727,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
12,1379,1,2,,50105913,446727,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
13,1422,1,1,,17404738,446727,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
14,1454,1,1,,50105913,446727,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
15,1457,1,1,,50105913,446727,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
16,1458,1,1,,50105913,446727,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
17,1459,1,1,,50105913,446727,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
18,1460,1,3,,50105913,446727,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
19,1461,1,2,,50105913,446727,Inconclusive,46395496.0,387129.0,25.1189,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
20,1463,1,1,,50105913,446727,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
21,1467,1,3,,50105913,446727,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
22,1468,1,1,,50105913,446727,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
23,1469,1,1,,50105913,446727,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
24,1471,2,1,,50105913,446727,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
25,1476,2,1,,50105913,446727,Inconclusive,281307097.0,,3.1623,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
26,1477,1,1,,50105913,446727,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
27,1478,2,1,,50105913,446727,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
28,1479,1,2,,50105913,446727,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
29,1487,1,1,,50105913,446727,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
30,1490,2,1,,50105913,446727,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
31,1519,1,3,,50105913,446727,Inconclusive,,,3.5481,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
32,1688,1,1,,50105913,446727,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
33,1705,1,2,,50105913,446727,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
34,1707,1,3,,50105913,446727,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
35,1708,1,3,,50105913,446727,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
36,1766,1,1,,50105913,446727,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
37,1766,1,1,,50105913,446727,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
38,1768,1,1,,50105913,446727,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
39,1768,1,1,,50105913,446727,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
40,1815,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
41,1816,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
42,1828,2,1,,50105913,446727,Inactive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
43,1865,1,1,,50105913,446727,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
44,1876,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
45,1877,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
46,1882,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
47,1883,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
48,1886,1,1,,50105913,446727,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
49,1948,1,1,,50105913,446727,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
50,1967,1,1,,50105913,446727,Inconclusive,4505907.0,5376.0,84.9214,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
51,2101,1,1,,50105913,446727,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
52,2107,1,1,,50105913,446727,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
53,2112,1,1,,50105913,446727,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
54,2147,1,1,,50105913,446727,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
55,2323,1,1,,50105913,446727,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
56,2326,1,1,,50105913,446727,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
57,2353,1,3,,50105913,446727,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
58,2364,1,2,,50105913,446727,Inconclusive,4557365.0,641.0,25.1189,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
59,2451,1,2,,50105913,446727,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
60,2517,2,1,,144204764,446727,Inactive,6980812.0,,56.2341,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
61,2528,1,2,,50105913,446727,Inconclusive,4557365.0,641.0,25.1189,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
62,2546,1,1,,50105913,446727,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
63,2549,1,1,,50105913,446727,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
64,2551,1,1,,50105913,446727,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
65,2662,2,1,,50105913,446727,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
66,2675,1,1,,50105913,446727,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
67,2732,1,1,,17404738,446727,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
68,2774,1,3,,92303475,446727,Inactive,,,,,LOPAC Circadian Assay,Screening,,
69,3058,6,2,,103202903,446727,Unspecified,,,150.0,EC50,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Confirmatory,14584954.0,
70,27595,3,3,,103202903,446727,Unspecified,,,,,Partition coefficient (logP),Other,12408726.0,
71,28488,5,2,,103202903,446727,Inconclusive,,,,,Catalytic rate constant was determined; ND: Not determined,Other,14584954.0,
72,30872,3,3,,103202903,446727,Unspecified,,,,,Antiherpes activity was tested as percent of control of plaque-formation against ACG (S1) virus by 30 uM of the compound,Other,2989522.0,
73,30875,3,3,,103202903,446727,Unspecified,,,,,Antiherpes activity was tested as percent of control of plaque-formation against ACG (Tr7) virus by 30 uM of the compound,Other,2989522.0,
74,41208,6,3,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BALB/3T3 cell line,Other,3005566.0,
75,42109,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BS-C-1A cell line,Other,3005566.0,
76,43638,3,3,,103202903,446727,Unspecified,,,,,Antiherpes activity was tested as percent of control of plaque-formation against BVdUr virus by 30 uM of the compound,Other,2989522.0,
77,44365,6,2,,103202903,446727,Unspecified,,,,,"Compound was evaluated for the cytotoxicity against human T-cell leukemia, CCRF-HSB-2 by using MTT assay.",Other,10206544.0,
78,45814,5,1,,103202903,446727,Unspecified,,,,,Dose that inhibited 50% cell growth of human T-lymphoid CEM cells compared with untreated control,Other,10891113.0,
79,45815,4,1,,103202903,446727,Unspecified,,,,,The mitochondrial toxicity was measured on human T-lymphoid CEM cells.,Other,10891113.0,
80,45931,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against CMV strain AD169 in human embryonic lung (HEL) cell culture,Other,8393114.0,
81,45932,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against CMV strain Davis in human embryonic lung (HEL) cell culture,Other,8393114.0,
82,52056,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus-induced cell growth by 50%,Other,8388474.0,
83,63591,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of HSV-1 (F) virus induced cytopathicity in E6SM cells,Other,9135038.0,
84,63592,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of HSV-1 (KOS) virus induced cytopathicity in E6SM cells,Other,9135038.0,
85,63593,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of HSV-1 (McIntyre) virus induced cytopathicity in E6SM cells,Other,9135038.0,
86,63595,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of HSV-2 (196) virus induced cytopathicity in E6SM cells,Other,9135038.0,
87,63596,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of HSV-2 (G) virus induced cytopathicity in E6SM cells,Other,9135038.0,
88,63597,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of HSV-2 (Lyons) virus induced cytopathicity in E6SM cells,Other,9135038.0,
89,63598,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of TK HSV-1 (B2006) virus induced cytopathicity in E6SM cells,Other,9135038.0,
90,63599,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of alteration of morphology in E6SM cells,Other,9135038.0,
91,63600,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of vaccinia virus induced cytopathicity in E6SM cells,Other,9135038.0,
92,63601,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in E6SM cells,Other,9135038.0,
93,63602,5,1,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to effect a microscopically visible change of cell morphology in human embryonic skin-muscle (E6SM) cell culture.,Other,9171871.0,
94,63604,6,3,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts,Other,11858989.0,
95,63605,10,1,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against herpes simplex virus type 1(KOS) in E6SM cell line(human embryonic skin-muscle fibroblasts),Other,11858989.0,
96,63607,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against thymidine kinase-deficient (TK-HSV-2G) virus in E6SM cell line(human embryonic skin-muscle fibroblasts),Other,11858989.0,
97,63609,6,3,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast,Other,11858989.0,
98,63615,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-1) strain F induced cytopathogenicity by 50%.,Other,7877148.0,
99,63617,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-1) strain KOS induced cytopathogenicity by 50%.,Other,7877148.0,
100,63619,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-1) strain McIntyre induced cytopathogenicity by 50%.,Other,7877148.0,
101,63623,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-2) strain G induced cytopathogenicity by 50%.,Other,7877148.0,
102,63625,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (HSV-2) strain Lyons induced cytopathogenicity by 50%.,Other,7877148.0,
103,63746,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 1 (TK- / TK+ HSV-1) strain VMW-1837 induced cytopathogenicity by 50%.,Other,7877148.0,
104,63748,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce herpes simplex virus type 2 (HSV-2) strain 196 induced cytopathogenicity by 50%.,Other,7877148.0,
105,63751,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce thymidine kinase deficient herpes simplex virus type 1 (TK- HSV-1) strain B2006 induced cytopathogenicity by 50%.,Other,7877148.0,
106,63754,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%.,Other,7877148.0,
107,63755,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum inhibitory concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50%,Other,7877148.0,
108,63757,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for antiviral activity against thymidine kinase-deficient (TK-HSV-1)virus in E6SM cell line(human embryonic skin-muscle fibroblasts),Other,11858989.0,
109,63758,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells,Other,7932543.0,
110,63759,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain),Other,7932543.0,
111,63760,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain),Other,7932543.0,
112,63761,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain),Other,7932543.0,
113,63762,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain),Other,7932543.0,
114,63763,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain),Other,7932543.0,
115,63764,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain),Other,7932543.0,
116,63765,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain),Other,7932543.0,
117,63766,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus,Other,7932543.0,
118,63767,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus,Other,7932543.0,
119,63768,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on E6SM cells for morphological alteration,Other,7932543.0,
120,63780,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell line,Other,3005566.0,
121,63945,6,2,,103202903,446727,Unspecified,,,,,Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
122,63947,6,3,,103202903,446727,Unspecified,,,,,Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM),Other,11858989.0,
123,63948,6,2,,103202903,446727,Unspecified,,,,,Tested for minimum cytotoxic concentration on virus-induced cytopathicity in E6SM cells,Other,8411010.0,
124,63953,6,2,,103202903,446727,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration of normal cell morphology in E6SM cells,Other,1652017.0,
125,63954,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit HSV-1 (F) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
126,64084,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit HSV-1 (KOS) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
127,64085,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit HSV-1 (McIntyre) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
128,64087,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit HSV-2(196) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
129,64088,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit HSV-2(G) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
130,64089,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit HSV-2(lyons) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
131,64090,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit TK-HSV-1 (B2006) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
132,64091,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit TK-HSV-1 (VMW1837) induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
133,64093,6,2,,103202903,446727,Unspecified,,,,,Concentration required to inhibit VSV induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
134,64103,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-1 (KOS) was measured,Other,2061920.0,
135,64104,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-1 (Mc Intyre) was measured,Other,2061920.0,
136,64105,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-1( F) was measured,Other,2061920.0,
137,64107,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-2 (196) was measured.,Other,2061920.0,
138,64108,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-2 (G) was measured,Other,2061920.0,
139,64109,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus HSV-2 (Lyons) was measured.,Other,2061920.0,
140,64110,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus TK- HSV-1 (B2006) was measured,Other,2061920.0,
141,64111,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus TK- HSV-1 (VMW1837) was measured,Other,2061920.0,
142,64114,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to to cause a microscopically detectable change in normal cell morphology,Other,2061920.0,
143,64117,6,2,,103202903,446727,Unspecified,,,,,Tested for minimum inhibitor concentration against vesicular stomatitis virus (VSV) in E6SM cells.,Other,8411010.0,
144,64118,6,2,,103202903,446727,Unspecified,,,,,Tested for minimum inhibitory concentration against HSV-1 (KOS strain) in E6SM cells,Other,8411010.0,
145,64120,6,2,,103202903,446727,Unspecified,,,,,Tested for minimum inhibitory concentration against Vaccinia virus in E6SM cells,Other,8411010.0,
146,65516,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E1SM cell line,Other,3005566.0,
147,65525,5,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration against E6SM cells,Other,,
148,65532,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for its antiviral activity in E6 cell cultures against herpes simplex virus type 1 (HSV-1) TK- B2006,Other,,
149,65533,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for its antiviral activity in E6 cell cultures against herpes simplex virus type 1 (HSV-1) TK- VMW 1837,Other,,
150,65534,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for its antiviral activity in E6 cell cultures against herpes simplex virus type 1 (HSV-1) strain KOS,Other,,
151,65535,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for its antiviral activity in E6 cell cultures against herpes simplex virus type 2 (HSV-2) strain G,Other,,
152,65536,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for its antiviral activity in E6 cell cultures against vaccinia virus (VV),Other,,
153,65537,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for its antiviral activity in E6 cell cultures against vesicular stomatitis virus (VSV),Other,,
154,65694,5,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against HSV-1 (KOS) in E6SM cells,Other,,
155,65695,5,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against HSV-2 (G) in E6SM cells,Other,,
156,65696,5,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against TK' HSV-1 (B2006) in E6SM cells,Other,,
157,65697,5,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against TK' HSV-1 (VMW 1837) in E6SM cells,Other,,
158,65699,5,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against Vaccinia virus in E6SM cells,Other,,
159,65701,6,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration required to cause alteration of normal E6SM cell culture morphology,Other,,
160,65705,6,2,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology,Other,11472207.0,
161,65707,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus in E6SM cell cultures,Other,11472207.0,
162,65708,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures,Other,11472207.0,
163,65709,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures,Other,11472207.0,
164,65710,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures,Other,11472207.0,
165,65711,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures,Other,11472207.0,
166,65712,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures,Other,11472207.0,
167,65844,6,2,,103202903,446727,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells,Other,8709116.0,
168,65995,6,2,,103202903,446727,Unspecified,,,,,Compound was evaluated for the minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology.,Other,9784109.0,
169,65996,5,3,,103202903,446727,Unspecified,,,,,Cytotoxicity (to alter cell morphology) against E6SM cell cultures,Other,,
170,66000,6,2,,103202903,446727,Unspecified,,,,,Tested for the minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in human embryonic skin muscle (E6SM) fibroblast cell cultures.,Other,7877148.0,
171,66001,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
172,66002,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
173,66003,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
174,66004,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
175,66005,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells.,Other,9046339.0,
176,66006,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
177,66007,6,2,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells.,Other,9046339.0,
178,66009,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1 TK-B2006 in E6SM cell cultures,Other,,
179,66010,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1 TK-VMW1837 in E6SM cell cultures,Other,,
180,66011,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1(KOS) in E6SM cell cultures,Other,,
181,66012,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-2 (G) in E6SM cell cultures,Other,,
182,66013,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Vaccinia virus in E6SM cell cultures,Other,,
183,66014,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Vesicular stomatitis virus in E6SM cell cultures,Other,,
184,66018,6,2,,103202903,446727,Unspecified,,,,,"Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-1 (TK-B2006) virus",Other,9784109.0,
185,66019,6,2,,103202903,446727,Unspecified,,,,,"Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against HSV-2 virus as means of G, 196, and Lyons strains",Other,9784109.0,
186,66020,6,2,,103202903,446727,Unspecified,,,,,"Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against KOS,F,McIntyre strains of HSV-1 virus.",Other,9784109.0,
187,66021,6,2,,103202903,446727,Unspecified,,,,,"Compound was evaluated for the minimum inhibition concentration required to reduce virus-induced cytopathogenicity by 50%, determined against Varicella-Zoster virus (YS)",Other,9784109.0,
188,66763,6,2,,103202903,446727,Unspecified,,,,,oncentration required to inhibit VV induced cytopathogenicity in E6SM cells by 50%.,Other,1652017.0,
189,66764,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (F) virus in E6SM cell culture,Other,3005566.0,
190,66765,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell culture,Other,3005566.0,
191,66766,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (McIntyre) virus in E6SM cell culture,Other,3005566.0,
192,66767,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-2 (196) virus in E6SM cell culture,Other,3005566.0,
193,66768,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-2 (G) virus in E6SM cell culture,Other,3005566.0,
194,66769,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-2 (Lyons) virus in E6SM cell culture,Other,3005566.0,
195,66770,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against TK-HSV-1 (B2006) virus in E6SM cell culture,Other,3005566.0,
196,66771,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against vaccinia virus in E6SM cell culture,Other,3005566.0,
197,66772,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against vesicular stomatitis virus in E6SM cell culture,Other,3005566.0,
198,66773,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of Urd,Other,3005566.0,
199,66774,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of dThd,Other,3005566.0,
200,66775,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of dUrd,Other,3005566.0,
201,66776,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence 0 ug/mL of 50 ug/mL of 6-aminothymine,Other,3005566.0,
202,66777,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL dThd,Other,3005566.0,
203,66778,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of Urd,Other,3005566.0,
204,66779,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of Urd and 50 ug/mL of 6-aminothymine,Other,3005566.0,
205,66780,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of dUrd,Other,3005566.0,
206,66781,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL of dUrd and 50 ug/mL of 6-aminothymine,Other,3005566.0,
207,66782,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL dThd,Other,3005566.0,
208,66783,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of Urd,Other,3005566.0,
209,66784,6,2,,103202903,446727,Unspecified,,,,,"The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of Urd and 50 ug/mL of 6-aminothymine,",Other,3005566.0,
210,66785,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of dUrd,Other,3005566.0,
211,66786,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL of dUrd and 50 ug/mL of 6-aminothymine,Other,3005566.0,
212,66787,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL dThd,Other,3005566.0,
213,66788,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of Urd,Other,3005566.0,
214,66789,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of Urd and 50 ug/mL of 6-aminothymine,Other,3005566.0,
215,66790,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of dUrd,Other,3005566.0,
216,66791,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL of dUrd and 50 ug/mL of 6-aminothymine,Other,3005566.0,
217,66795,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 3 ug/mL dThd,Other,3005566.0,
218,66796,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 30 ug/mL dThd,Other,3005566.0,
219,66797,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 300 ug/mL dThd,Other,3005566.0,
220,66799,6,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 50 ug/mL of 6-aminothymine,Other,3005566.0,
221,66933,7,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of specified concentrations of 6-aminothymine,Other,3005566.0,
222,66934,7,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of specified concentrations of benzylacyclouridine,Other,3005566.0,
223,66938,4,4,,103202903,446727,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in E6SM,Other,10691698.0,
224,66939,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-1 virus in E6SM cells,Other,1326633.0,
225,66940,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-2 virus in E6SM cells,Other,1326633.0,
226,66941,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- HSV-1 virus in E6SM cells,Other,1326633.0,
227,66942,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vaccinia virus in E6SM cells,Other,1326633.0,
228,66943,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in E6SM cells,Other,1326633.0,
229,66958,6,2,,103202903,446727,Unspecified,,,50.0,EC50,Effective concentration to show 50% of activity was measured on Epstein Barr virus(EBV) cell culture,Confirmatory,10891113.0,
230,67101,6,2,,103202903,446727,Unspecified,,,300.0,EC50,Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells,Confirmatory,12408726.0,
231,68118,6,2,,103202903,446727,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration of normal ESM cell morphology.,Other,1319491.0,
232,68119,6,2,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(B2006) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
233,68120,6,2,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(VMW 1837) induced cytopathogenicity in by 50% ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
234,68121,6,2,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
235,68122,6,2,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-2(G) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
236,68123,6,2,,103202903,446727,Unspecified,,,,,Concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
237,68124,6,2,,103202903,446727,Unspecified,,,,,Concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.,Other,1319491.0,
238,68252,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
239,68253,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
240,68254,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
241,68255,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
242,68256,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM),Other,8176708.0,
243,68257,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM),Other,8176708.0,
244,68278,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration required for morphologic alteration in normal cell in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
245,71873,7,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against FM3A TK- cell line,Other,2391680.0,
246,71878,5,1,,103202903,446727,Unspecified,,,,,Concentration required to cause a microscopically detectable alteration of normal cell morphology,Other,2391680.0,
247,72044,5,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against FM3A/0 cell line,Other,2391680.0,
248,72045,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against FM3A/0 mammary carcinoma cells,Other,3039140.0,
249,72048,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against FM3A/TK- cells,Other,3039140.0,
250,72158,7,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against FMBA TK-/HSV-2 TK+ cell line,Other,2391680.0,
251,81024,6,3,,103202903,446727,Inconclusive,,,,,The compound was tested for anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells;d ='not determined',Other,9836626.0,
252,81025,6,3,,103202903,446727,Inconclusive,,,,,The compound was tested for anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells;d ='not determined',Other,9836626.0,
253,81026,6,3,,103202903,446727,Active,,,0.001,IC50,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain,Confirmatory,10411487.0,
254,81028,6,3,,103202903,446727,Active,,,0.005,IC50,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain,Confirmatory,10411487.0,
255,81030,6,3,,103202903,446727,Unspecified,,,50.0,IC50,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain,Confirmatory,10411487.0,
256,81032,6,3,,103202903,446727,Unspecified,,,50.0,IC50,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain,Confirmatory,10411487.0,
257,81035,8,3,,103202903,446727,Inconclusive,,,,,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain; Not determined,Other,10411487.0,
258,81037,8,3,,103202903,446727,Inconclusive,,,,,The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain; Not determined,Other,10411487.0,
259,81038,6,3,,103202903,446727,Unspecified,,,100.0,IC50,The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%,Confirmatory,10411487.0,
260,81040,7,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration against HEL cell morphology.,Other,12217359.0,
261,81046,6,3,,103202903,446727,Unspecified,,,,,"In vitro antiviral activity and cytotoxicity, and minimum inhibitory concentration required to reduce cell growth by 50% in HEL cell culture",Other,2061920.0,
262,81049,6,3,,103202903,446727,Unspecified,,,,,Concentration required to cause 50% reduction in HEL cell growth.,Other,1652017.0,
263,81051,6,3,,103202903,446727,Unspecified,,,,,Concentration required to inhibit CMV (AD-169) induced cytopathogenicity in HEL cells by 50%.,Other,1652017.0,
264,81053,6,3,,103202903,446727,Unspecified,,,,,Concentration required to inhibit CMV (Davis) induced cytopathogenicity in HEL cells by 50%.,Other,1652017.0,
265,81056,6,3,,103202903,446727,Unspecified,,,,,Concentration required to inhibit TK-VZV (07-1) induced cytopathogenicity in HEL cells by 50%.,Other,1652017.0,
266,81058,6,3,,103202903,446727,Unspecified,,,,,Concentration required to inhibit TK-VZV (YSR) induced cytopathogenicity in HEL cells by 50%.,Other,1652017.0,
267,81189,6,3,,103202903,446727,Unspecified,,,,,Concentration required to inhibit VZV (YS) induced cytopathogenicity in HEL cells by 50%.,Other,1652017.0,
268,81191,6,3,,103202903,446727,Unspecified,,,,,Concentration required to inhibit VZV (oka) induced cytopathogenicity in HEL cells by 50%.,Other,1652017.0,
269,81193,6,3,,103202903,446727,Unspecified,,,,,Inhibitory concentration required to inhibit cell growth by 50% in human embryonic lung (HEL) cell culture,Other,8393114.0,
270,81196,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- VZV virus in HEL cells,Other,1326633.0,
271,81197,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against VZV virus in HEL cells,Other,1326633.0,
272,81199,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus VSV was measured,Other,2061920.0,
273,81200,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity in embryonic skin muscle (E6SM) cell culture of virus VV was measured,Other,2061920.0,
274,81201,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus CMV (AD169) was measured,Other,2061920.0,
275,81202,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus CMV (Davis) was measured,Other,2061920.0,
276,81203,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus TK- VZV (07-1) was measured,Other,2061920.0,
277,81204,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus TK- VZV (YS-R) was measured,Other,2061920.0,
278,81205,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus VZS (OKA) was measured,Other,2061920.0,
279,81206,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced plaque formation in HEL cell culture of virus VZS (YS) was measured,Other,2061920.0,
280,81218,4,5,,103202903,446727,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology HEL,Other,10691698.0,
281,81219,3,5,,103202903,446727,Unspecified,,,,,Cytotoxicity concentration required to reduce cell growth by 50% in HEL,Other,10691698.0,
282,81371,8,1,,103202903,446727,Unspecified,,,170.0,ID50,Inhibitory dose for HELF cell proliferation during 3-day treatment period,Confirmatory,2828623.0,
283,81378,5,3,,103202903,446727,Unspecified,,,,,Cytotoxic concentration required to reduce cell growth HEL cells (after 3 days) by 50 %,Other,,
284,81757,6,1,,103202903,446727,Unspecified,,,,,Minimum toxic effect against HEp-2 cells.,Other,4067994.0,
285,81898,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HEp-2M cell line,Other,3005566.0,
286,82532,4,1,,103202903,446727,Unspecified,,,,,50% Cytostatic concentration required to inhibit human erythroleukemic (HEL) cell proliferation,Other,9171871.0,
287,82551,6,3,,103202903,446727,Unspecified,,,,,"Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.",Other,7877148.0,
288,82854,6,3,,103202903,446727,Unspecified,,,400.0,IC50,Compound was evaluated for the anti-viral activity against HEL cells,Confirmatory,10579812.0,
289,82867,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK+ VZV strain OKA,Other,,
290,82870,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against TK- Varicella-Zoster virus (VZV) strain YS/R,Other,,
291,82872,4,3,,103202903,446727,Inconclusive,,,,,Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain AD-169; no data,Other,,
292,82874,4,3,,103202903,446727,Inconclusive,,,,,Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against cytomegalovirus (CMV) strain Davis; no data,Other,,
293,82875,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against herpes simplex virus type 1 (HSV-1) TK- strain 07/1,Other,,
294,82876,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in human embryonic lung (HEL) cell cultures against Varicella-Zoster virus (VZV) strain YS,Other,,
295,82895,6,3,,103202903,446727,Unspecified,,,,,Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.,Other,7877148.0,
296,82896,6,3,,103202903,446727,Unspecified,,,,,Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%,Other,7877148.0,
297,83020,6,3,,103202903,446727,Unspecified,,,,,Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.,Other,7877148.0,
298,83022,6,3,,103202903,446727,Unspecified,,,,,Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.,Other,7877148.0,
299,83023,6,3,,103202903,446727,Unspecified,,,,,Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.,Other,7877148.0,
300,83024,6,3,,103202903,446727,Unspecified,,,,,Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.,Other,7877148.0,
301,83034,7,3,,103202903,446727,Unspecified,,,,,Compound was evaluated for the cytotoxicity against HEL cells,Other,10579812.0,
302,83035,6,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration to reduce the HEL cell proliferation by 50%,Other,8709116.0,
303,83042,5,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration against human embryonic lung (HEL) cells,Other,,
304,83044,6,3,,103202903,446727,Unspecified,,,,,Tested for cytotoxic activity in human embryonic lung fibroblast (HEL),Other,11858989.0,
305,83046,6,3,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human embryonic HEL cells.,Other,9046339.0,
306,83047,6,3,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human embryonic HEL cells.,Other,9046339.0,
307,83048,6,3,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human embryonic HEL cells.,Other,9046339.0,
308,83049,6,3,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human embryonic HEL cells.,Other,9046339.0,
309,83052,6,3,,103202903,446727,Unspecified,,,,,50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human embryonic HEL cells.,Other,9046339.0,
310,83146,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity against VZV (Ellen) in human lung fibroblast (HLF-1) cells,Other,3037079.0,
311,83181,6,3,,103202903,446727,Unspecified,,,,,Concentration required to reduce VZV-07/1-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
312,83182,6,3,,103202903,446727,Unspecified,,,,,Concentration required to reduce VZV-YS/R-TK- plaque formation by 50% in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
313,83183,6,3,,103202903,446727,Unspecified,,,,,Concentration required to reduce varicella zoster virus(VZV)OKA plaque formation by 50% at 20 plaque forming units(PFU) in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
314,83184,6,3,,103202903,446727,Unspecified,,,,,Concentration required to reduce varicella zoster virus (VZV)YS-TK-PFU plaque formation by 50% in human embryonic lung (HEL) cell cultures.,Other,1319491.0,
315,83185,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in HeLa cell cultures against Coxsackie virus type B4,Other,,
316,83186,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in HeLa cell cultures against polio virus type 1,Other,,
317,83187,5,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in HeLa cell cultures against vesicular stomatitis virus (VSV),Other,,
318,83191,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of TK VZV (07/1) virus plaque formation in HEL cells,Other,9135038.0,
319,83192,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of TK-VZV (YS/R) virus plaque formation in HEL cells,Other,9135038.0,
320,83193,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of VZV (OKA) virus plaque formation in HEL cells,Other,9135038.0,
321,83194,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of VZV (YS) virus plaque formation in HEL cells,Other,9135038.0,
322,83195,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory conc. for 50% inhibition of growth in HEL cells,Other,9135038.0,
323,83196,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (AD-169) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
324,83197,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Cytomegalovirus (CMV) (Davis) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
325,83198,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce TK Varicella Zoster virus (VZV) (07/1) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
326,83199,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required for antiviral activity to reduce Varicella Zoster virus (VZV) (Oka) induced cytopathicity in human embryonic lung cells (HEL),Other,8176708.0,
327,83201,6,3,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration to reduce cytopathicity by 50% in proliferation of human embryonic lung cells (HEL),Other,8176708.0,
328,83204,6,3,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against thymidine kinase deficient Varicella zoster virus in human embryonic lung fibroblasts,Other,11858989.0,
329,83205,6,3,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against thymidine kinase wild type Varicella zoster virus in human embryonic lung fibroblast,Other,11858989.0,
330,83207,6,3,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (AD-169 strain),Other,7932543.0,
331,83325,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Cytomegalovirus virus (Davis strain),Other,7932543.0,
332,83328,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (07/1 strain),Other,7932543.0,
333,83329,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against TK-Varicella zoster virus (YS-R strain),Other,7932543.0,
334,83331,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (OKA strain),Other,7932543.0,
335,83332,6,2,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells against Varicella zoster virus (YS strain),Other,7932543.0,
336,83333,6,3,,103202903,446727,Unspecified,,,,,The minimum inhibitory concentration was measured on HEL cells in cell growth,Other,7932543.0,
337,83350,4,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against TK' VZV (07/1) in HEL cells,Other,,
338,83351,4,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against TK' VZV (YS/R) in HEL cells,Other,,
339,83352,4,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against VZV (OKA) in HEL cells,Other,,
340,83353,4,1,,103202903,446727,Unspecified,,,,,Minimum antiviral concentration required to reduce virus-induced cytopathogenicity against VZV (YS) in HEL cells,Other,,
341,83356,5,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration required to cause alteration of normal human epithelial cell lining (HEL) morphology in HEL cells,Other,,
342,83497,5,1,,103202903,446727,Unspecified,,,,,Inhibition of cell proliferation expressed as CC50,Other,9836626.0,
343,83499,7,3,,103202903,446727,Unspecified,,,,,Cytotoxic concentration reducing HEL cell growth by 50%.,Other,12217359.0,
344,83500,5,3,,103202903,446727,Inconclusive,,,,,Cytotoxic concentration to reduce HEL cell growth by 50%; ND denotes no data,Other,12217359.0,
345,83522,6,2,,103202903,446727,Unspecified,,,,,Anti-VZV activity against 07/1 TK- in HEL cells,Other,9836626.0,
346,83524,6,2,,103202903,446727,Unspecified,,,,,Anti-VZV activity against OKA strain TK+ in HEL cells,Other,9836626.0,
347,83526,6,2,,103202903,446727,Unspecified,,,,,Anti-VZV activity against YS TK+ in HEL cells,Other,9836626.0,
348,83528,6,2,,103202903,446727,Unspecified,,,,,Anti-VZV activity against YS/R TK- in HEL cells,Other,9836626.0,
349,83534,5,3,,103202903,446727,Inconclusive,,,,,Minimum cytotoxic concentration against HEL cell morphology; ND denotes no data,Other,12217359.0,
350,83535,6,3,,103202903,446727,Unspecified,,,50.0,IC50,Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells,Confirmatory,10411487.0,
351,83716,8,1,,103202903,446727,Active,,,0.05,ID50,Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures,Confirmatory,2828623.0,
352,83893,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration against HSV-1.,Other,4067994.0,
353,83895,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (F)) virus-induced cytopathicity by 50%,Other,8388474.0,
354,83896,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (KOS)) virus-induced cytopathicity by 50%,Other,8388474.0,
355,83897,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (McIntyre)) virus-induced cytopathicity by 50%,Other,8388474.0,
356,84071,5,1,,103202903,446727,Unspecified,,,,,"Compound was evaluated for antiviral activity against HSV-1(TK-, strain B2006)",Other,6321735.0,
357,84072,5,1,,103202903,446727,Unspecified,,,,,Compound was evaluated for antiviral activity against HSV-1(strain KOS),Other,6321735.0,
358,84084,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
359,84085,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (F) in E6SM cell culture,Other,10691698.0,
360,84086,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (G) in E6SM cell culture,Other,10691698.0,
361,84217,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
362,84218,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
363,84223,6,2,,103202903,446727,Unspecified,,,50.0,EC50,Effective concentration to show 50% of activity was measured on herpes simplex virus-1 KOS strain cell culture.,Confirmatory,10891113.0,
364,84225,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (KOS) in E6SM cell culture,Other,10691698.0,
365,84228,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
366,84230,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (McIntyre) in E6SM cell culture,Other,10691698.0,
367,84238,6,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce herpes simplex virus-1 (HSV- (TK-) B2006 strain)-induced cytopathicity,Other,9171871.0,
368,84239,6,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce herpes simplex virus-1 (HSV- (TK-) VMW 1837 strain)-induced cytopathicity,Other,9171871.0,
369,84240,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (TK-/TK+VMW1837) in E6SM cell culture,Other,10691698.0,
370,84243,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-1 (TK-KOS ACV) in E6SM cell culture,Other,10691698.0,
371,84256,5,1,,103202903,446727,Unspecified,,,,,Compound was evaluated for the antiviral activity against Herpes simplex virus type 1 (HSV-1) VR-3 strain by using plaque reduction assay.,Other,10206544.0,
372,84407,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against Thymidine kinase deficient(TK-) HSV-1 of Acyclovir,Other,11708929.0,
373,84409,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against TK-/TK+ HSV-1 of VMW 837,Other,11708929.0,
374,84415,6,2,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus (thymidine kinase deficient herpes simplex virus ( HSV-1 (B2006) in primary rabbit kidney cells,Other,3039140.0,
375,84417,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus( HSV-1-F) strain in primary rabbit kidney cells,Other,3039140.0,
376,84418,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus( HSV-1-KOS) strain in primary rabbit kidney cells,Other,3039140.0,
377,84420,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus( HSV-1-McIntyre) strain in primary rabbit kidney cells,Other,3039140.0,
378,84588,10,1,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against F strain of human Herpes Simplex Virus-1 (HSV-1),Other,11708929.0,
379,84590,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against KOS strain of human Herpes Simplex Virus -1,Other,11708929.0,
380,84591,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against McIntyre strain of human Herpes Simplex Virus-1,Other,11708929.0,
381,84604,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce cytopathogenicity of Herpes simplex virus type 2 (strain G) by 50% in primary rabbit kidney (PRK) cells,Other,6092636.0,
382,84605,8,1,,103202903,446727,Active,,,4.2,ID50,Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2.,Confirmatory,2521518.0,
383,84760,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-2(196),Other,3007759.0,
384,84761,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-2(G),Other,3007759.0,
385,84762,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-2(Lyons),Other,3007759.0,
386,84763,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-2(196),Other,3959027.0,
387,84765,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-2(G),Other,3959027.0,
388,84766,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-2(Lyons),Other,3959027.0,
389,84767,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-2 virus induced cytopathogenicity in rabbit cell kidney culture (196 cells),Other,2826786.0,
390,84768,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-2 virus induced cytopathogenicity in rabbit cell kidney culture (G cells),Other,2826786.0,
391,84769,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-2 virus induced cytopathogenicity in rabbit cell kidney culture (Lyons cells),Other,2826786.0,
392,84777,5,3,,103202903,446727,Unspecified,,,,,Compound was tested for the antiviral activity against herpes simplex virus-2 (HSV-2) G strain,Other,,
393,84933,6,2,,103202903,446727,Unspecified,,,150.0,EC50,Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%,Confirmatory,11585457.0,
394,84950,8,1,,103202903,446727,Active,,,27.0,ID50,Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures,Confirmatory,2828623.0,
395,84953,5,1,,103202903,446727,Unspecified,,,,,Compound was evaluated for antiviral activity against HSV-2(strain G),Other,6321735.0,
396,84961,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration against HSV-2.,Other,4067994.0,
397,84963,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (196)) virus-induced cytopathicity by 50%,Other,8388474.0,
398,84964,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (G)) virus-induced cytopathicity by 50%,Other,8388474.0,
399,84965,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (Lyons)) virus-induced cytopathicity by 50%,Other,8388474.0,
400,85112,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
401,85113,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-2 (196) in E6SM cell culture,Other,10691698.0,
402,85119,6,2,,103202903,446727,Unspecified,,,50.0,EC50,Effective concentration to show 50% of activity was measured on herpes simplex virus-2 333 strain cell culture.,Confirmatory,10891113.0,
403,85120,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
404,85127,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
405,85129,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against HSV-2 (Lyons) in E6SM cell culture,Other,10691698.0,
406,85246,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HSF (VGS) cell line,Other,3005566.0,
407,85253,5,1,,103202903,446727,Unspecified,,,,,Compound was evaluated for the antiviral activity against Herpes simplex virus type 2 (HSV-2) MS strain by using plaque reduction assay.,Other,10206544.0,
408,85372,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against HSV type 1 strain F in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
409,85373,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against HSV type 1 strain KOS in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
410,85374,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against HSV type 1 strain Mc Intyre in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
411,85378,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against HSV type 2 strain 196 in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
412,85379,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against HSV type 2 strain G in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
413,85380,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against HSV type 2 strain Lyons in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
414,85402,3,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-1 kinase mutant resistant to B3(BVdU) was determined at a conc of 30 uM,Other,2822932.0,
415,85405,3,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-1 kinase mutant resistant to SCS(parental) was determined at a conc of 30 uM,Other,2822932.0,
416,85407,3,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-1 kinase mutant resistant to Tr7(ACV) was determined at a conc of 30 uM,Other,2822932.0,
417,85418,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus( HSV-2-196 strain in primary rabbit kidney cells,Other,3039140.0,
418,85419,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus( HSV-2-G) strain in primary rabbit kidney cells,Other,3039140.0,
419,85420,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex virus( HSV-2-lyons) strain in primary rabbit kidney cells,Other,3039140.0,
420,85421,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against 196 strain of human Herpes Simplex Virus-2,Other,11708929.0,
421,85422,10,1,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against G strain of human Herpes Simplex Virus-2,Other,11708929.0,
422,85423,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against Lyons strain of human Herpes Simplex Virus-2,Other,11708929.0,
423,85432,6,2,,103202903,446727,Active,,,0.1,Ki,Inhibition constant against HSV-1 TK,Confirmatory,14584954.0,
424,85556,5,1,,103202903,446727,Unspecified,,,,,Antiviral activity against various strains of Herpes Simplex virus type I,Other,6292425.0,
425,85558,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce cytopathogenicity of Herpes simplex virus type 1 (strain KOS) by 50% in primary rabbit kidney (PRK) cells,Other,6092636.0,
426,85559,8,1,,103202903,446727,Active,,,0.6,ID50,Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1.,Confirmatory,2521518.0,
427,85712,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-1 (F),Other,3007759.0,
428,85713,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-1 (KOS),Other,3007759.0,
429,85714,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-1 (McIntyre),Other,3007759.0,
430,85715,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-1(F),Other,3959027.0,
431,85716,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-1(KOS),Other,3959027.0,
432,85717,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes Simplex Virus-1 (McIntyre),Other,3959027.0,
433,85718,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-1 virus induced cytopathogenicity in rabbit cell kidney culture (F cells),Other,2826786.0,
434,85719,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-1 virus induced cytopathogenicity in rabbit cell kidney culture (KOS cells),Other,2826786.0,
435,85720,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce HSV-1 virus induced cytopathogenicity in rabbit cell kidney culture (McIntyre cells),Other,2826786.0,
436,85828,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against herpes simplex virus type 1 (HSV-1) determined in baby hamster kidney cells,Other,6887201.0,
437,85865,5,3,,103202903,446727,Unspecified,,,,,Compound was tested for the antiviral activity against herpes simplex virus-1 (HSV-1) KOS strain,Other,,
438,85866,5,3,,103202903,446727,Unspecified,,,,,Compound was tested for the antiviral activity against herpes simplex virus-1 thymidine kinase deficient (HSV-1 TK-) B2006 strain,Other,,
439,85867,5,3,,103202903,446727,Unspecified,,,,,Compound was tested for the antiviral activity against herpes simplex virus-1 thymidine kinase deficient (HSV-1 TK-) VMW 1837 strain,Other,,
440,85883,7,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce herpes simplex virus-1 (HSV-1 KOS strain)-induced cytopathicity,Other,9171871.0,
441,85884,6,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce herpes simplex virus-2 (HSV-2 G strain)-induced cytopathicity,Other,9171871.0,
442,85893,6,2,,103202903,446727,Active,,,2.7,EC50,Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%,Confirmatory,11585457.0,
443,86022,6,2,,103202903,446727,Active,,,1.5,EC50,Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%,Confirmatory,11585457.0,
444,86023,6,2,,103202903,446727,Unspecified,,,150.0,EC50,Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%,Confirmatory,11585457.0,
445,86207,3,4,,103202903,446727,Unspecified,,,,,Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL,Other,3037079.0,
446,86208,3,4,,103202903,446727,Unspecified,,,,,Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL,Other,3037079.0,
447,86209,3,4,,103202903,446727,Unspecified,,,,,Proliferation of Hep-2 cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL,Other,3037079.0,
448,86215,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-1 (Brand) in human epithelial (Hep-2) cells,Other,3037079.0,
449,86216,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-2 (K979) in human epithelial (Hep-2) cells,Other,3037079.0,
450,86349,5,3,,103202903,446727,Unspecified,,,,,Cytotoxicity (to alter cell morphology) against HeLa cells,Other,,
451,86350,5,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration against HeLa cells,Other,,
452,86354,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Coxsackie virus B4 in HeLa cells,Other,,
453,86355,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Polio virus-I in HeLa cells,Other,,
454,86356,5,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Vesicular stomatitis virus in HeLa cells,Other,,
455,86492,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against coxsackie-B4 virus in human epithelial cell line,Other,11858989.0,
456,86500,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for antiviral activity against VSV-virus in human epithelial cells,Other,11858989.0,
457,86514,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HeLa cell line,Other,3005566.0,
458,87137,7,2,,103202903,446727,Unspecified,,,,,Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
459,87144,6,2,,103202903,446727,Unspecified,,,,,Tested for cytotoxic activity in human epithelial cell line (HeLa),Other,11858989.0,
460,87146,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
461,87147,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
462,87149,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
463,87153,7,2,,103202903,446727,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against HeLa cells (human carcinoma) infected with VSV, Coxs, B4, polio-1 virus",Other,2158560.0,
464,87157,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in HeLa cells,Other,1326633.0,
465,87159,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against respiratory syncytial virus in HeLa cells,Other,1326633.0,
466,87160,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in HeLa cells,Other,1326633.0,
467,87191,7,1,,103202903,446727,Active,,,,,Concentration that protects by 50% the cytopathic effect induced by herpes simplex virus - 1.,Other,2981323.0,
468,87194,3,3,,103202903,446727,Unspecified,,,,,Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (CL101) virus by 30 uM of the compound,Other,2989522.0,
469,87197,3,3,,103202903,446727,Unspecified,,,,,Antiherpes activity was tested as percent of control of plaque-formation against HSV-1 (KOS) virus by 30 uM of the compound,Other,2989522.0,
470,87299,7,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of specified concentrations of 6-aminothymine,Other,3005566.0,
471,87322,3,3,,103202903,446727,Unspecified,,,,,Antiherpes activity was tested as percent of control of plaque-formation against HSV-2 (333) virus by 30 uM of the compound,Other,2989522.0,
472,87444,7,1,,103202903,446727,Unspecified,,,,,Concentration that induces 50% cell toxicity was determined using monolayers of uninfected HeLa cells,Other,2981323.0,
473,87456,4,4,,103202903,446727,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in HeLa,Other,10691698.0,
474,87478,3,3,,103202903,446727,Active,,,,,Tested for in vitro anti-HSV-1 activity; active,Other,2299637.0,
475,87503,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce HSV-1 (F) strain-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
476,87504,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce HSV-1 (KOS) strain-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
477,87505,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce HSV-1 (McIntyre) strain-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
478,87506,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain F,Other,3027328.0,
479,87507,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain KOS.,Other,3027328.0,
480,87508,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Herpes simplex virus type 1 (HSV-1) strain McIntyre,Other,3027328.0,
481,87821,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity expressed as minimum HSV-2 (Lyons) strain-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
482,87823,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce HSV-2 (196) strain-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
483,87824,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce HSV-2 (G) strain-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
484,87826,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain 196.,Other,3027328.0,
485,87827,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain G,Other,3027328.0,
486,87828,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Herpes simplex virus type 2 (HSV-2) strain Lyons,Other,3027328.0,
487,87842,3,6,,103202903,446727,Unspecified,,,,,Effect on thymidine kinase in the herpes simplex type-1 infected cells,Other,4009596.0,
488,87843,8,1,,103202903,446727,Active,,,0.019,ED50,Antiviral activity against herpes simplex type-1 expressed as ED50,Confirmatory,4009596.0,
489,87844,7,1,,103202903,446727,Active,,,,,Antiviral activity against herpes simplex type-1 expressed as ED90,Other,4009596.0,
490,87978,8,1,,103202903,446727,Active,,,,,Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-1 in PRK cells,Other,2842506.0,
491,87979,8,1,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-1(thymidine kinase deficient) in PRK cells,Other,2842506.0,
492,87984,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration which is active against herpes simplex virus type-1 (HSV-1); value ranges from 0.007-0.01 ug/mL,Other,2167981.0,
493,87993,3,6,,103202903,446727,Unspecified,,,,,Effect on thymidine kinase in the herpes simplex type-2 infected cells,Other,4009596.0,
494,87994,8,1,,103202903,446727,Active,,,0.23,ED50,Antiviral activity against herpes simplex type-2 expressed as ED50,Confirmatory,4009596.0,
495,87995,7,1,,103202903,446727,Active,,,,,Antiviral activity against herpes simplex type-2 expressed as ED90,Other,4009596.0,
496,88117,8,1,,103202903,446727,Active,,,,,Minimum inhibitory concentration causing 50% inhibition of cytopathic effect induced by HSV-2 in PRK cells,Other,2842506.0,
497,88195,6,2,,103202903,446727,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells,Other,8709116.0,
498,88277,7,2,,103202903,446727,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against KOS, F, McIntyre strains of Herpes simplex virus (HSV-1) in primary rabbit kidney cells",Other,2158560.0,
499,88278,7,2,,103202903,446727,Unspecified,,,,,Evaluated for minimum inhibitory concentration against TK-B2006 strain of Herpes simplex virus (HSV-1) in primary rabbit kidney cells,Other,2158560.0,
500,88297,7,2,,103202903,446727,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against G,196, Lyons strains of Herpes simplex virus (HSV-2) in primary rabbit kidney cells",Other,2158560.0,
501,90760,7,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce cytomegalovirus (CMV AD-169 strain)-induced cytopathicity,Other,9171871.0,
502,90761,7,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce cytomegalovirus (CMV Davis strain)-induced cytopathicity,Other,9171871.0,
503,90775,5,2,,103202903,446727,Inconclusive,,,,,Antiviral activity against human cytomegalovirus AD-169 which reduces virus plaque formation by 50%; ND denotes no data,Other,12217359.0,
504,90777,5,2,,103202903,446727,Inconclusive,,,,,Antiviral activity against human cytomegalovirus Davis which reduces virus plaque formation by 50%; ND denotes no data,Other,12217359.0,
505,96607,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against L1210 cells,Other,3039140.0,
506,96824,5,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against L1210 cell line,Other,2391680.0,
507,103155,6,2,,103202903,446727,Unspecified,,,,,"The compound was tested for its antiviral activity against HSV-1 (KOS) virus in M-21 (GM137) cell line,",Other,3005566.0,
508,104933,6,3,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in MO cell line,Other,3005566.0,
509,105822,7,1,,103202903,446727,Unspecified,,,100.0,MIC50,Minimum inhibitory concentration required to reduce cytopathogenicity of Cytomegalovirus Virus (CMV) in MRC-5 cells by 50%.,Confirmatory,1654428.0,
510,105823,8,1,,103202903,446727,Active,,,0.03,MIC50,Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-1 (HSV-1) in MRC -5 cells by 50%.,Confirmatory,1654428.0,
511,105824,8,1,,103202903,446727,Active,,,0.02,MIC50,Minimum inhibitory concentration required to reduce cytopathogenicity of Varicella Zoster Virus (VZV) in MRC-5 cells by 50%.,Confirmatory,1654428.0,
512,106002,6,3,,103202903,446727,Unspecified,,,100.0,IC50,Inhibitory activity against human cytomegalovirus (HCMV) strain AD169 in MRC-5 cells.,Confirmatory,8576922.0,
513,106003,6,2,,103202903,446727,Active,,,1.0,IC50,Inhibitory activity against varicella zoster virus (VZV) strain G31 in MRC-5 cells.,Confirmatory,8576922.0,
514,110459,3,4,,103202903,446727,Unspecified,,,,,"Cumulative mortality in percent of HSV-1 infected mice, after peroral administration of 100 mg/kg of compound",Other,2842506.0,
515,111521,3,3,,103202903,446727,Unspecified,,,,,Tested for the appearance of skin lesions or paralysis of the legs after 39 days when administered intraperitoneally at 100 mg/kg per day,Other,2391680.0,
516,111522,3,3,,103202903,446727,Unspecified,,,,,Tested for the appearance of skin lesions or paralysis of the legs after 52 days when applied topically at 10% after 52 days,Other,2391680.0,
517,112423,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce leukemia L1210 cell growth in mice,Other,6302254.0,
518,112441,6,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against incorporation of deoxy-[methyl.3H-]-thymidine (dThd) into the DNA of murine leukemia L1210 cell cultures,Other,6302254.0,
519,118654,6,1,,103202903,446727,Unspecified,,,,,Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when administered intraperitoneally at 100 mg/kg per day after 39 days,Other,2391680.0,
520,118655,6,1,,103202903,446727,Unspecified,,,,,Compound was evaluated in nu/nu mice infected with TK- HSV-1 (VMW-1837) to increase the mean survival time when applied topically at 10% after 52 days,Other,2391680.0,
521,120293,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through at a dose 25 mg/kg per day,Other,4067994.0,
522,120294,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 100 mg/kg per day,Other,4067994.0,
523,120295,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 10 mg/kg per day,Other,4067994.0,
524,120296,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 1 mg/kg per day,Other,4067994.0,
525,120297,5,3,,103202903,446727,Inconclusive,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 2.5 mg/kg per day; NT=Not tested,Other,4067994.0,
526,120298,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 50 mg/kg per day,Other,4067994.0,
527,120299,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through intraperitoneal at a dose 5 mg/kg per day,Other,4067994.0,
528,120300,5,3,,103202903,446727,Inconclusive,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 100 mg/kg per day; NT=Not tested,Other,4067994.0,
529,120301,5,3,,103202903,446727,Inconclusive,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 10 mg/kg per day; NT=Not tested,Other,4067994.0,
530,120302,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 2.5 mg/kg per day,Other,4067994.0,
531,120303,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 25 mg/kg per day,Other,4067994.0,
532,120304,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 50 mg/kg per day,Other,4067994.0,
533,120305,3,4,,103202903,446727,Unspecified,,,,,In vivo evaluation for the percent survivors in systemic HSV-1 infection of Mice administered through oral route at a dose 5 mg/kg per day,Other,4067994.0,
534,125368,5,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against Molt/4F cell line,Other,2391680.0,
535,133911,7,1,,103202903,446727,Unspecified,,,,,Mean time survival (MTS) of the mice at the end of 28 or 49 days.,Other,2329561.0,
536,134096,3,3,,103202903,446727,Unspecified,,,,,Topical treatment of intracutaneous HSV-1(KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO),Other,2329561.0,
537,134097,3,3,,103202903,446727,Unspecified,,,,,Topical treatment of intracutaneous HSV-1(KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO),Other,2329561.0,
538,134098,3,3,,103202903,446727,Unspecified,,,,,Topical treatment of intracutaneous HSV-1(KOS) herpes simplex virus type 1 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO),Other,2329561.0,
539,134099,3,3,,103202903,446727,Unspecified,,,,,Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 0.3% concentration (v/v in DMSO),Other,2329561.0,
540,134100,3,3,,103202903,446727,Unspecified,,,,,Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 1% concentration (v/v in DMSO),Other,2329561.0,
541,134101,3,3,,103202903,446727,Unspecified,,,,,Topical treatment of intracutaneous TK- herpes simplex virus type 1 of strain VMW 1837 infection of Nu/nu mice for mean day of appearance of skin lesions and/or paralysis of the hind legs at 3% concentration (v/v in DMSO),Other,2329561.0,
542,139990,6,2,,103202903,446727,Active,,,23.0,Ki,Inhibition constant assumed to reflect the affinity for the transport site in mouse erythrocytes,Confirmatory,7877148.0,
543,147625,6,2,,103202903,446727,Active,,,0.005,EC50,Antiviral activity against OKA strain of thymidine kinase positive(TK+) Varicella-Zoster Virus (VZV),Confirmatory,14584954.0,
544,151170,6,2,,103202903,446727,Unspecified,,,400.0,CC50,Cytotoxic concentration that causes growth inhibition of VZV infected Osteosarcoma cells,Confirmatory,14584954.0,
545,151172,7,2,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration that causes alterations of VZV infected Osteosarcoma cell morphology,Other,14584954.0,
546,154154,6,2,,103202903,446727,Unspecified,,,225.0,CC50,Cytotoxic concentration for the inhibition of P3HR-1 cell growth,Confirmatory,12408726.0,
547,156542,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in PRK cell line,Other,3005566.0,
548,156685,5,1,,103202903,446727,Unspecified,,,,,Inhibitory concentration required to reduce incorporation of 2-deoxythymidine (dThd) into DNA of Primary Rabbit kidney (PRK) cell cultures,Other,6092636.0,
549,156686,5,1,,103202903,446727,Unspecified,,,,,Inhibitory concentration required to reduce incorporation of 2-deoxyuridine (dUrd) into DNA of Primary Rabbit kidney (PRK) cell cultures,Other,6092636.0,
550,156694,7,2,,103202903,446727,Unspecified,,,,,Evaluation in PRK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
551,156700,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-1 (KOS) in Primary Rabbit Kidney (PRK) cells,Other,3037079.0,
552,156701,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-2 (G) in Primary Rabbit Kidney (PRK) cells,Other,3037079.0,
553,156702,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-1(F) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
554,156703,7,2,,103202903,446727,Unspecified,,,,,Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
555,156704,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-1 (McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
556,156705,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
557,156706,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-2(196) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
558,156707,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
559,156708,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against herpes simplex virus-2(Lyons) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
560,156709,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
561,156710,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
562,156860,7,2,,103202903,446727,Unspecified,,,,,The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of specified concentrations of 6-aminothymine,Other,3005566.0,
563,161450,7,2,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of rabbit kidney cell morphology,Other,2547072.0,
564,161451,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against 196 strain of herpes simplex virus-2 in primary rabbit kidney cell cultures,Other,2547072.0,
565,161452,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against B2006 strain of thymidine kinase deficient (TK-) herpes simplex virus-1 in primary rabbit kidney cell cultures,Other,2547072.0,
566,161453,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against F strain of herpes simplex virus-1 in primary rabbit kidney cell cultures,Other,2547072.0,
567,161454,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against G strain of herpes simplex virus-2 in primary rabbit kidney cell cultures,Other,2547072.0,
568,161455,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against KOS strain of herpes simplex virus-1 in primary rabbit kidney cell cultures,Other,2547072.0,
569,161456,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Lyons strain of herpes simplex virus-2 in primary rabbit kidney cell cultures,Other,2547072.0,
570,161457,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against McIntyre strain of herpes simplex virus-1 in primary rabbit kidney cell cultures,Other,2547072.0,
571,161458,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VMW 1837 strain of thymidine kinase deficient (TK-) herpes simplex virus-1 in primary rabbit kidney cell cultures,Other,2547072.0,
572,161459,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus in primary rabbit kidney cell cultures,Other,2547072.0,
573,161460,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus in primary rabbit kidney cell cultures,Other,2547072.0,
574,165523,5,1,,103202903,446727,Unspecified,,,,,"Concentration of compound required to inhibit [1',2'-3H]dUrd incorporation into host cell DNA by 50% in primary rabbit kidney cell cultures",Other,6321735.0,
575,165524,5,1,,103202903,446727,Unspecified,,,,,Concentration of compound required to inhibit [methyl-3H]dThd incorporation into host cell DNA by 50% in primary rabbit kidney cell cultures,Other,6321735.0,
576,165526,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce Herpes simplex virus type 1 induced cytopathogenicity in primary rabbit kidney (PRK) cell cultures,Other,6302254.0,
577,165527,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce Herpes simplex virus type 2 induced cytopathogenicity in primary rabbit kidney (PRK) cell cultures,Other,6302254.0,
578,165528,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce Vaccinia virus induced cytopathogenicity in primary rabbit kidney (PRK) cell cultures,Other,6302254.0,
579,165542,5,1,,103202903,446727,Unspecified,,,,,"Inhibitory activity against incorporation of deoxy-[1',2'-3H]uridine (dUrd) into the DNA of uninfected primary rabbit kidney (PRK) cell cultures",Other,6302254.0,
580,165543,5,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against incorporation of deoxy-[methyl.3H-]-thymidine (dThd) into the DNA of uninfected primary rabbit kidney (PRK) cell cultures,Other,6302254.0,
581,165784,5,1,,103202903,446727,Unspecified,,,,,Inhibitory activity against Raji cell line,Other,2391680.0,
582,166985,4,1,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration causing microscopically detectable alteration of normal cell morphology of rabbit kidney cells,Other,2826786.0,
583,167133,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 ((KOS),Other,6300403.0,
584,167134,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (F),Other,6300403.0,
585,167135,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-1 (McIntyre),Other,6300403.0,
586,167136,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (196),Other,6300403.0,
587,167137,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (G),Other,6300403.0,
588,167138,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against HSV-2 (Lycons),Other,6300403.0,
589,167139,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vaccinia virus,Other,6300403.0,
590,167140,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathogenicity in primary rabbit kidney cell cultures by 50% against Vesicular stomatitis virus,Other,6300403.0,
591,167150,7,1,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit,Other,2842506.0,
592,167744,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-1 (F) in rabbit kidney cell,Other,2391680.0,
593,167746,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-1 (KOS) in rabbit kidney cell,Other,2391680.0,
594,167747,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-1 (McIntyre) in rabbit kidney cell,Other,2391680.0,
595,167877,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-1 TK- B2006 in rabbit kidney cell,Other,2391680.0,
596,167879,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-1 TK- VMW 1837 in rabbit kidney cell,Other,2391680.0,
597,167881,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-2 (196) in rabbit kidney cell,Other,2391680.0,
598,167883,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-2 (G) in rabbit kidney cell,Other,2391680.0,
599,167884,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against herpes simplex virus-2 (Lyons) in rabbit kidney cell,Other,2391680.0,
600,167886,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against vaccinia virus in rabbit kidney cell,Other,2391680.0,
601,167887,6,2,,103202903,446727,Unspecified,,,,,Antiviral Activity against vesicular stomatitis virus in rabbit kidney cell,Other,2391680.0,
602,167889,7,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum cytotoxic concentration (MCC) upon preincubation of rabbit kidney cells in medium containing 10% fetal calf serum at 37 degree Celsius for 24 hr,Other,2329561.0,
603,209372,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against HSV-1 TK gene transformed TK deficient FM3A cells,Other,3039140.0,
604,209373,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain B2006,Other,2329561.0,
605,209374,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against TK- herpes simplex virus type 1 (TK- HSV-1) with strain VMW 1837,Other,2329561.0,
606,209530,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (B2006) virus-induced cytopathicity by 50%,Other,8388474.0,
607,209531,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (VMW 1837) virus-induced cytopathicity by 50%,Other,8388474.0,
608,209532,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against TK-HSV type 1 strain B2006 in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
609,209536,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce TK-VZV (07-1) virus-induced cytopathicity by 50%,Other,8388474.0,
610,209537,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce TK-VZV (YS/R) virus-induced cytopathicity by 50%,Other,8388474.0,
611,209538,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against TK-VZV strain 07-1 in human embryonic lung (HEL) cell culture,Other,8393114.0,
612,209539,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against TK-VZV strain YS-R in human embryonic lung (HEL) cell culture,Other,8393114.0,
613,209957,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in T-21 (LR) cell line,Other,3005566.0,
614,210531,12,1,,103202903,446727,Unspecified,125437.0,,2870.0,IC50,Inhibitory concentration against Herpes simplex virus type 1 thymidine kinase(HSV-1 TK),Confirmatory,11392548.0,
615,210687,5,5,,103202903,446727,Inconclusive,,,,,Catalytic turnover constant of compound against HSV-1 thymidine kinase; ND denotes not determined,Other,14584954.0,
616,210688,9,3,,103202903,446727,Active,,,0.1,Ki,Binding affinity constant against HSV-1 thymidine kinase,Confirmatory,14584954.0,
617,210698,9,2,,103202903,446727,Active,,,0.3,IC50,Binding affinity towards HSV-1 thymidine kinase,Confirmatory,8941385.0,
618,216038,6,2,,103202903,446727,Active,,,1.4,IC50,Inhibitory activity against herpes simplex virus type 1 (HSV-1) strain SC16 in Vero cells.,Confirmatory,8576922.0,
619,216040,6,2,,103202903,446727,Active,,,10.0,IC50,Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells.,Confirmatory,8576922.0,
620,216153,6,2,,103202903,446727,Active,,,0.005,EC50,Effective concentration against TK+ Varicella-Zoster Virus (VZV) OKA strain,Confirmatory,14584954.0,
621,216154,6,2,,103202903,446727,Active,,,0.008,EC50,Effective concentration against TK+ Varicella-Zoster Virus (VZV)YS strain,Confirmatory,14584954.0,
622,216155,6,2,,103202903,446727,Unspecified,,,150.0,EC50,Effective concentration against TK- Varicella-Zoster Virus (VZV) 07/1 strain,Confirmatory,14584954.0,
623,216156,6,2,,103202903,446727,Unspecified,,,150.0,EC50,Effective concentration against TK- Varicella-Zoster Virus (VZV) YS/R strain,Confirmatory,14584954.0,
624,216158,6,2,,103202903,446727,Unspecified,,,,,Anti-viral activity which is required for the inhibition of VZV (Varicella zoster virus ),Other,2167981.0,
625,216166,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration which is active against Varicella zoster virus (VZV); value ranges from 0.0002-0.003 ug/mL,Other,2167981.0,
626,216169,6,2,,103202903,446727,Unspecified,,,,,Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using 07/1 (TK-) strain.,Other,8709116.0,
627,216170,6,2,,103202903,446727,Unspecified,,,,,Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using OKA (TK+) strain,Other,8709116.0,
628,216171,6,2,,103202903,446727,Unspecified,,,,,Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS(TK+) strain.,Other,8709116.0,
629,216172,6,2,,103202903,446727,Unspecified,,,,,Minimum Inhibition Concentration (MIC) for activity against Varicella-Zoster Virus(VZV) using YS/R (TK-) strain.,Other,8709116.0,
630,216197,6,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration (to alter cell morphology) against vero cells,Other,,
631,216198,6,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration against vero cells,Other,,
632,216200,6,2,,103202903,446727,Unspecified,,,,,Tested for cytotoxic activity in African green monkey kidney cells (Vero),Other,11858989.0,
633,216203,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Coxsackie virus in vero cells,Other,,
634,216204,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Parainfluenza-3 virus in vero cells,Other,,
635,216205,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Reovirus-1 in vero cells,Other,,
636,216206,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against forest virus in vero cells,Other,,
637,216207,6,3,,103202903,446727,Unspecified,,,,,Antiviral activity (to reduce virus-induced cytopathogenicity) against Sindbis virus in vero cells,Other,,
638,216208,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in vero cell cultures against Coxsackie virus type B4,Other,,
639,216209,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in vero cell cultures against Parainfluenza virus type 3,Other,,
640,216210,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in vero cell cultures against Reovirus type 1,Other,,
641,216211,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in vero cell cultures against forest virus,Other,,
642,216212,6,3,,103202903,446727,Unspecified,,,,,Evaluated in vitro for antiviral activity in vero cell cultures against Sindbis virus,Other,,
643,216247,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce vesicular stomatis virus-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
644,216300,6,2,,103202903,446727,Unspecified,,,144.0,EC50,Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain 07,Confirmatory,10579812.0,
645,216301,6,2,,103202903,446727,Unspecified,,,300.0,EC50,Compound was evaluated for the inhibition of VZV (TK-) thymidine kinases Strain YS-R,Confirmatory,10579812.0,
646,216302,6,2,,103202903,446727,Active,,,0.003,EC50,Compound was evaluated for the inhibition of VZV strains of OKA,Confirmatory,10579812.0,
647,216303,6,2,,103202903,446727,Active,,,0.006,EC50,Compound was evaluated for the inhibition of VZV strains of YS,Confirmatory,10579812.0,
648,216346,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against Punta toro virus in African green monkey kidney cell (Vero),Other,11858989.0,
649,216347,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against Reo-1 virus in African green monkey kidney cell (Vero),Other,11858989.0,
650,216348,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against Sindbis virus in African green monkey kidney cell (Vero),Other,11858989.0,
651,216349,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against coxsackie B-4 virus in African green monkey kidney cell (Vero),Other,11858989.0,
652,216350,6,2,,103202903,446727,Unspecified,,,,,Tested for antiviral activity against parainfluenza virus in african green monkey kidney cell (Vero),Other,11858989.0,
653,216382,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity in rabbit cell kidney culture,Other,2826786.0,
654,216388,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce cytopathogenicity of Vesicular stomatitis virus by 50% in primary rabbit kidney (PRK) cells,Other,6092636.0,
655,216408,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus,Other,3007759.0,
656,216410,7,2,,103202903,446727,Unspecified,,,,,Evaluated for minimum inhibitory concentration against Vesicular stomatitis virus (VSV) in primary rabbit kidney cells,Other,2158560.0,
657,216472,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity was tested against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50%,Other,12217359.0,
658,216473,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity was tested against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50%,Other,12217359.0,
659,216475,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity was tested against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50%,Other,12217359.0,
660,216479,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity was tested against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50%,Other,12217359.0,
661,216509,6,2,,103202903,446727,Unspecified,,,,,The compound was tested for its antiviral activity against HSV-1 (KOS) virus in vero cell line,Other,3005566.0,
662,216533,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vesicular stomatitis virus,Other,2329561.0,
663,216539,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Vesicular stomatitis virus.,Other,3027328.0,
664,216540,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus,Other,3959027.0,
665,217419,3,4,,103202903,446727,Unspecified,,,,,Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 100 ug/mL,Other,3037079.0,
666,217420,3,4,,103202903,446727,Unspecified,,,,,Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 30 ug/mL,Other,3037079.0,
667,217421,3,4,,103202903,446727,Unspecified,,,,,Proliferation of Vero cells by propagation on day 4 by measuring optical density (absorbance) at 330 ug/mL,Other,3037079.0,
668,217480,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce VSV virus-induced cytopathicity by 50%,Other,8388474.0,
669,217483,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against VSV in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
670,217484,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against VSV,Other,11708929.0,
671,217485,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce vesicular somatitis virus (VSV (YS)) virus-induced cytopathicity by 50%,Other,8388474.0,
672,217488,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against VV in human embryonic skin muscle (ESM) fibroblast cell culture,Other,8393114.0,
673,217489,6,2,,103202903,446727,Unspecified,,,,,Minimal inhibitory concentration to reduce virus-induced cytopathicity against VV,Other,11708929.0,
674,217490,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce vaccinia virus (VV) virus-induced cytopathicity by 50%,Other,8388474.0,
675,217496,6,2,,103202903,446727,Unspecified,,,50.0,EC50,The effective concentration to show 50% of activity was measured on varicella zoster virus(Ellen) cell culture,Confirmatory,10891113.0,
676,217497,6,2,,103202903,446727,Active,,,0.05,EC50,Effective concentration to show 50% of activity was measured on varicella zoster virus(VZV) cell culture,Confirmatory,10891113.0,
677,217503,6,2,,103202903,446727,Unspecified,,,400.0,CC50,cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus,Confirmatory,11150169.0,
678,217504,7,2,,103202903,446727,Unspecified,,,,,"Minimal cytotoxic concentration, the concentration required to cause a microscopically visible alteration of normal cell morphology.",Other,11150169.0,
679,217508,6,2,,103202903,446727,Active,,,0.003,EC50,Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%,Confirmatory,11585457.0,
680,217510,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce Varicella-Zoster virus (VZV (Oka)) virus-induced cytopathicity by 50%,Other,8388474.0,
681,217593,8,1,,103202903,446727,Active,,,0.07,ED50,In vitro antiviral activity was determined by plaque-reduction assay in HSV-1(strain 2931) infected Vero cell monolayers,Confirmatory,6317862.0,
682,217594,8,1,,103202903,446727,Active,,,12.95,ED50,In vitro antiviral activity was determined by plaque-reduction assay in HSV-2 (strain G) infected Vero cell monolayers,Confirmatory,6317862.0,
683,217648,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against VZV (OKA) in HEL cells,Other,10691698.0,
684,217651,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against VZV (TK-07/1) in HEL cells,Other,10691698.0,
685,217654,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against VZV (TK-YS/R) in HEL cells,Other,10691698.0,
686,217657,7,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration was determined against VZV (YS) in HEL cells,Other,10691698.0,
687,217659,6,2,,103202903,446727,Active,,,0.003,EC50,"Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.",Confirmatory,11150169.0,
688,217663,5,1,,103202903,446727,Unspecified,,,,,Compound was evaluated for the antiviral activity against Varicella-Zoster virus (VZV) Oka strain by using plaque reduction assay.,Other,10206544.0,
689,217665,6,2,,103202903,446727,Unspecified,,,150.0,EC50,"Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.",Confirmatory,11150169.0,
690,217670,6,2,,103202903,446727,Active,,,0.003,EC50,"Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.",Confirmatory,11150169.0,
691,217673,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against VZV strain OKA in human embryonic lung (HEL) cell culture,Other,8393114.0,
692,217674,6,2,,103202903,446727,Unspecified,,,,,Inhibitory concentration against VZV strain YS in human embryonic lung (HEL) cell culture,Other,8393114.0,
693,217757,5,1,,103202903,446727,Unspecified,,,,,In vitro antiviral activity against HSV-1(strain HFEM) in Vero cells,Other,3009815.0,
694,217758,5,1,,103202903,446727,Unspecified,,,,,In vitro antiviral activity against HSV-2(strain 196) in Vero cells,Other,3009815.0,
695,217760,5,1,,103202903,446727,Unspecified,,,,,Cytotoxicity was measured by determining the incorporation of [methyl-3H]thymidine into DNA of Vero cells,Other,3009815.0,
696,217768,4,1,,103202903,446727,Unspecified,,,,,Inhibitory dose required to reduce the viability of vero cells by 50%,Other,1654428.0,
697,217806,6,2,,103202903,446727,Unspecified,,,150.0,EC50,"Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.",Confirmatory,11150169.0,
698,217807,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce vaccinia virus-induced cytopathogenicity in primary rabbit kidney cell cultures,Other,6265638.0,
699,217819,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce vaccinia virus induced cytopathogenicity in rabbit cell kidney culture,Other,2826786.0,
700,217829,5,1,,103202903,446727,Unspecified,,,,,Concentration required to reduce cytopathogenicity of vaccinia virus by 50% in primary rabbit kidney (PRK) cells,Other,6092636.0,
701,217888,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-1 (Brand) in Vero cells,Other,3037079.0,
702,217889,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV-2 (K979) in Vero cells,Other,3037079.0,
703,217890,7,2,,103202903,446727,Unspecified,,,,,"Evaluated for minimum inhibitory concentration against Vero cells (African green monkey) infected with PV-3, RV-1, SV, Coxs B4, SFV virus",Other,2158560.0,
704,217899,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in Vero cells,Other,1326633.0,
705,217900,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against junin virus in Vero cells,Other,1326633.0,
706,217901,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against measles virus in Vero cells,Other,1326633.0,
707,217903,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against reo type 1 virus in Vero cells,Other,1326633.0,
708,217904,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against semliki forest virus in Vero cells,Other,1326633.0,
709,217905,6,2,,103202903,446727,Unspecified,,,,,Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against sindbis virus in Vero cells,Other,1326633.0,
710,217971,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against Vaccinia virus in primary rabbit kidney cells,Other,3039140.0,
711,217975,7,2,,103202903,446727,Unspecified,,,,,50% effective concentration required to reduce vaccinia virus-induced cytopathicity,Other,9171871.0,
712,217983,5,1,,103202903,446727,Unspecified,,,,,Compound was evaluated for its antiviral activity against vaccinia,Other,6321735.0,
713,217995,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vaccinia virus,Other,3007759.0,
714,217998,7,2,,103202903,446727,Unspecified,,,,,Evaluated for minimum inhibitory concentration against Vaccinia virus (VV) in primary rabbit kidney cells,Other,2158560.0,
715,218000,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against vaccinia virus,Other,2329561.0,
716,218050,8,1,,103202903,446727,Active,,,12.0,MIC50,Minimum inhibitory concentration required to reduce cytopathogenicity of Herpes Virus-2 (HSV-2) in vero cells by 50%.,Confirmatory,1654428.0,
717,218132,6,2,,103202903,446727,Unspecified,,,,,Evaluation of antiviral activity against Vaccinia virus,Other,3027328.0,
718,218133,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vaccinia virus,Other,3959027.0,
719,218227,4,4,,103202903,446727,Unspecified,,,,,Cytotoxicity concentration required to microscopically detectable alteration of cell morphology in Vero,Other,10691698.0,
720,218249,7,2,,103202903,446727,Unspecified,,,,,Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology,Other,1324318.0,
721,218251,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
722,218252,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against forest virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
723,218253,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against Sindbis virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
724,218254,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
725,218369,6,2,,103202903,446727,Unspecified,,,,,Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells,Other,8709116.0,
726,218374,7,1,,103202903,446727,Unspecified,,,,,Inhibitory dose required to reduce the growth of vero cells by 50% over a 4 day period.,Other,8576922.0,
727,218375,6,1,,103202903,446727,Unspecified,,,,,Cytotoxic dose of compound required to reduce the viability of normal uninfected vero cells by 50%.,Other,8289203.0,
728,218376,7,2,,103202903,446727,Unspecified,,,,,Evaluation for antiviral activity against reo virus-1 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%),Other,1324318.0,
729,218385,8,1,,103202903,446727,Unspecified,,,191.0,ID50,Cytotoxic activity against vero cells was evaluated.,Confirmatory,4009596.0,
730,218509,7,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce coxsackie virus B4-induced cytopathicity in vero cells,Other,9171871.0,
731,218510,7,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce parainfluenza-3-induced cytopathicity in vero cells,Other,9171871.0,
732,218511,7,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce reovirus-1-induced cytopathicity in vero cells,Other,9171871.0,
733,218512,7,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce sindbis virus-induced cytopathicity in vero cells,Other,9171871.0,
734,218513,7,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce vesicular stomatitis virus (VSV)-induced cytopathicity in vero cells,Other,9171871.0,
735,218518,8,1,,103202903,446727,Active,,,0.3,ED50,Antiviral activity against HSV-1 (Herpes simplex virus) in vero cells,Confirmatory,8289203.0,
736,218519,8,1,,103202903,446727,Active,,,6.8,ED50,Antiviral activity against HSV-2 (Herpes simplex virus) in vero cells,Confirmatory,8289203.0,
737,220079,6,2,,103202903,446727,Active,,,0.008,EC50,Antiviral activity against YS strain of thymidine kinase positive(TK+) Varicella-Zoster Virus (VZV),Confirmatory,14584954.0,
738,220080,6,2,,103202903,446727,Unspecified,,,150.0,EC50,Antiviral activity against YS/R strain of thymidine kinase negative(TK-) Varicella-Zoster Virus (VZV),Confirmatory,14584954.0,
739,221302,7,3,,103202903,446727,Unspecified,,,,,Compound was tested for antiviral activity against herpes simplex Vassicular stomatitis in primary rabbit kidney cells,Other,3039140.0,
740,221318,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains F,Other,2329561.0,
741,221319,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains KOS,Other,2329561.0,
742,221320,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-1 (HSV-1) with strains McIntyre,Other,2329561.0,
743,221325,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains 196,Other,2329561.0,
744,221326,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains G,Other,2329561.0,
745,221459,6,2,,103202903,446727,Unspecified,,,,,Evaluated for the minimum inhibitory concentration (MIC) in primary rabbit kidney (PRK) by 50% against herpes simplex virus type-2 (HSV-2) with strains Lyons,Other,2329561.0,
746,221798,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against human B-lymphoblast Raji/0 cells,Other,3039140.0,
747,221799,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against thymidine kinase deficient human B-lymphoblast Raji/0 cells,Other,3039140.0,
748,221967,7,2,,103202903,446727,Unspecified,,,,,Compound was tested for antitumor activity against human T-lymphoblast Molt/4F cells,Other,3039140.0,
749,222129,6,2,,103202903,446727,Unspecified,,,,,Minimum concentration required to cause a microscopically detectable alteration of cell morphology,Other,8388474.0,
750,224691,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 0,Other,8388474.0,
751,224692,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 12,Other,8388474.0,
752,224693,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 20,Other,8388474.0,
753,224694,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 3,Other,8388474.0,
754,224695,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 6,Other,8388474.0,
755,224696,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 100 mg/kg at day 9,Other,8388474.0,
756,224697,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 0,Other,8388474.0,
757,224698,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 12,Other,8388474.0,
758,224699,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 20,Other,8388474.0,
759,224700,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 3,Other,8388474.0,
760,224701,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 6,Other,8388474.0,
761,224702,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 25 mg/kg at day 9,Other,8388474.0,
762,224703,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 0,Other,8388474.0,
763,224704,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 12,Other,8388474.0,
764,224705,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 20,Other,8388474.0,
765,224706,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 3,Other,8388474.0,
766,224707,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 6,Other,8388474.0,
767,224708,3,4,,103202903,446727,Unspecified,,,,,Survival of mice after intraperitoneal infection with HSV-1 (KOS) and oral administration of 250 mg/kg at day 9,Other,8388474.0,
768,227702,3,4,,103202903,446727,Unspecified,,,,,"Ratio of ID50 for dThd or dUrd incorporation to ID50 for HSV-1, HSV-2 or VV(whatever was lowest)",Other,6092636.0,
769,228285,6,2,,103202903,446727,Unspecified,,,400.0,CC50,Cytotoxic concentration that produces 50% inhibition of cell growth.,Confirmatory,14584954.0,
770,228729,6,2,,103202903,446727,Unspecified,,,,,Minimal cytotoxic concentration (MCC) to cause a microscopically detectable change in normal cell morphology,Other,11708929.0,
771,228732,7,2,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration that causes microscopically detectable alterations of cell morphology,Other,14584954.0,
772,228733,6,2,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation.,Other,9046339.0,
773,228763,6,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology,Other,,
774,229025,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
775,229235,6,2,,103202903,446727,Unspecified,,,,,Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle,Other,12459010.0,
776,232770,3,3,,103202903,446727,Unspecified,,,,,Selectivity index against HSV-1 was determined as CD50/ED50 ratio,Other,8289203.0,
777,232771,3,3,,103202903,446727,Unspecified,,,,,Selectivity index against HSV-2 was determined as CD50/ED50 ratio,Other,8289203.0,
778,235555,3,3,,103202903,446727,Inconclusive,,,,,Ratio of Cytotoxicity concentration to that of virus-inhibitory concentration;d ='not determined'.,Other,9836626.0,
779,235593,3,3,,103202903,446727,Unspecified,,,,,Ratio of ID50/ID90 in HSV-1 infected cells,Other,4009596.0,
780,235596,3,3,,103202903,446727,Unspecified,,,,,Ratio of ID50/ID90 in HSV-2 infected cells,Other,4009596.0,
781,244771,7,3,,103202903,446727,Unspecified,,,,,Concentration required to cause a microscopically visible alteration of cell morphology in HEL cells,Other,16000005.0,
782,244773,7,3,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration required to cause a microscopically visible alteration of HEL fibroblast cell morphology,Other,15801851.0,
783,244774,6,2,,103202903,446727,Unspecified,,,,,Minimum cytotoxic concentration that caused a microscopically detectable alteration of cell morphology in E6SM Cell Culture,Other,15481985.0,
784,245891,6,3,,103202903,446727,Unspecified,,,249.0,CC50,Cytotoxic concentration required to reduce HEL cell growth,Confirmatory,15801851.0,
785,245943,6,3,,103202903,446727,Unspecified,,,400.0,CC50,Concentration required to inhibit cell proliferation in HEL cells by 50%,Confirmatory,16000005.0,
786,246259,6,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
787,246308,6,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
788,246311,6,3,,103202903,446727,Unspecified,,,150.0,EC50,Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
789,246312,6,3,,103202903,446727,Unspecified,,,400.0,EC50,Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
790,246314,6,3,,103202903,446727,Unspecified,,,60.0,EC50,Concentration required to inhibit vaccinia virus induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
791,246316,6,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
792,246356,6,2,,103202903,446727,Unspecified,,,,,Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture,Other,15481985.0,
793,246409,6,3,,103202903,446727,Unspecified,,,500.0,EC50,Concentration required to inhibit vesicular stomatitis virus induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
794,246414,6,3,,103202903,446727,Active,,,0.16,EC50,Concentration required to inhibit herpes simplex virus type 1 induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
795,246415,6,3,,103202903,446727,Unspecified,,,300.0,EC50,Concentration required to inhibit herpes simplex virus type 2 induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
796,246450,6,3,,103202903,446727,Unspecified,,,100.0,EC50,Concentration required to inhibit human cytomegalovirus strain AD169 induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
797,246451,6,3,,103202903,446727,Unspecified,,,100.0,EC50,Concentration required to inhibit human cytomegalovirus strain Davis induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
798,246464,6,3,,103202903,446727,Active,,,0.03,EC50,Concentration required to inhibit Varicella-Zoster virus (strain OKA) induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
799,246470,6,3,,103202903,446727,Active,,,0.03,EC50,Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line,Confirmatory,15801851.0,
800,246474,6,3,,103202903,446727,Unspecified,,,108.0,EC50,Concentration required to inhibit Varicella-Zoster virus (strain 07/1) induced cytopathogenicity in HEL cells by 50%,Confirmatory,16000005.0,
801,246487,6,3,,103202903,446727,Unspecified,,,103.0,EC50,Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line,Confirmatory,15801851.0,
802,246523,6,3,,103202903,446727,Active,,,0.003,EC50,Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
803,246524,6,2,,103202903,446727,Unspecified,,,50.0,EC50,Concentration required to inhibit human immunodeficiency virus-1 (strain ROD) induced cytopathogenicity in CEM cells by 50%,Confirmatory,16000005.0,
804,246529,6,3,,103202903,446727,Active,,,0.003,EC50,Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
805,246532,6,2,,103202903,446727,Unspecified,,,50.0,EC50,Concentration required to inhibit human immunodeficiency virus-1 (strain IIIb) induced cytopathogenicity in CEM cells by 50%,Confirmatory,16000005.0,
806,246561,6,3,,103202903,446727,Active,,,29.0,EC50,Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
807,246562,6,3,,103202903,446727,Unspecified,,,56.0,EC50,Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture,Confirmatory,15481985.0,
808,246614,6,3,,103202903,446727,Unspecified,,,100.0,EC50,Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection,Confirmatory,15801851.0,
809,246626,6,3,,103202903,446727,Unspecified,,,100.0,EC50,Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection,Confirmatory,15801851.0,
810,257886,7,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HEL cells,Other,16420056.0,
811,257887,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vero cells,Other,16420056.0,
812,257888,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HeLa cells,Other,16420056.0,
813,257889,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells,Other,16420056.0,
814,257890,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 G strain in HEL cells,Other,16420056.0,
815,257891,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus in HEL cells,Other,16420056.0,
816,257892,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus in HEL cells,Other,16420056.0,
817,257893,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells,Other,16420056.0,
818,257894,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Parainfluenza-3 virus in vero cells,Other,16420056.0,
819,257895,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Reovirus 1 in vero cells,Other,16420056.0,
820,257896,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus in vero cells,Other,16420056.0,
821,257897,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in vero cells,Other,16420056.0,
822,257898,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus in vero cells,Other,16420056.0,
823,257899,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus in HeLa cells,Other,16420056.0,
824,257900,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in HeLa cells,Other,16420056.0,
825,257901,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus in HeLa cells,Other,16420056.0,
826,258989,6,2,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against Varicella-Zoster virus YS strain,Confirmatory,16392824.0,
827,258990,6,2,,103202903,446727,Unspecified,,,99.0,EC50,Antiviral activity against Varicella-Zoster virus 07/1 strain,Confirmatory,16392824.0,
828,258991,6,2,,103202903,446727,Unspecified,,,126.0,EC50,Antiviral activity against Varicella-Zoster virus YS/R strain,Confirmatory,16392824.0,
829,258992,6,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against human cytomegalovirus AD169 strain,Confirmatory,16392824.0,
830,258993,6,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against human cytomegalovirus Davis strain,Confirmatory,16392824.0,
831,258994,7,3,,103202903,446727,Unspecified,,,,CC50,Cytotoxic activity against cultured human embryonic lung (HEL) cells,Confirmatory,16392824.0,
832,260291,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK+ VZV OKA in human embryonic lung cells,Other,16480257.0,
833,260292,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK- VZV 07/10 in human embryonic lung cells,Other,16480257.0,
834,260293,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity as determined by alteration in the cell morphology of HEL cells,Other,16480257.0,
835,260294,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells,Other,16480257.0,
836,275067,6,4,,103202903,446727,Active,,,0.096,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,17181162.0,
837,275068,6,2,,103202903,446727,Unspecified,,,300.0,EC50,Antiviral activity against HSV2 in HEL cells,Confirmatory,17181162.0,
838,275069,6,2,,103202903,446727,Active,,,2.4,EC50,Antiviral activity against vaccinia virus in HEL cells,Confirmatory,17181162.0,
839,275070,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against vesicular somatitis virus in HEL cells,Confirmatory,17181162.0,
840,275071,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against Coxsackie B4 virus in HeLa cells,Confirmatory,17181162.0,
841,275072,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against RSV in HeLa cells,Confirmatory,17181162.0,
842,275073,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against para influenza 3 virus in Vero cells,Confirmatory,17181162.0,
843,275074,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against reovirus 1 in Vero cells,Confirmatory,17181162.0,
844,275075,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against Sindbis virus in Vero cells,Confirmatory,17181162.0,
845,275076,6,2,,103202903,446727,Unspecified,,,500.0,EC50,Antiviral activity against Punta Toro virus in Vero cells,Confirmatory,17181162.0,
846,275086,6,4,,103202903,446727,Unspecified,,,300.0,EC50,Antiviral activity against HSV1 KOS in HEL cells,Confirmatory,17181162.0,
847,275087,6,3,,103202903,446727,Unspecified,,,500.0,CC50,Cytotoxicity against HEL cells,Confirmatory,17181162.0,
848,275088,6,2,,103202903,446727,Unspecified,,,500.0,CC50,Cytotoxicity against HeLa cells,Confirmatory,17181162.0,
849,275089,6,2,,103202903,446727,Unspecified,,,500.0,CC50,Cytotoxicity against Vero cells,Confirmatory,17181162.0,
850,280175,6,4,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
851,280176,7,4,,103202903,446727,Unspecified,,,,,Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
852,280177,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
853,280178,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
854,280179,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VZV OKA in HEL cells assessed as inhibition of plaque formation,Other,17298047.0,
855,280180,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK- VZV 07-1 in HEL cells assessed as inhibition of plaque formation,Other,17298047.0,
856,280186,5,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days,Other,17298047.0,
857,280188,5,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as inhibition of cell growth after 3 days,Other,17298047.0,
858,280189,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HIV1 3B in human CEM cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
859,280190,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HIV2 ROD in human CEM cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
860,280191,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against MSV in mouse C3H cells assessed as inhibition of virus-induced transformation after 6 days,Other,17298047.0,
861,280192,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
862,280193,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
863,280194,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
864,280195,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
865,280196,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
866,280197,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
867,280198,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
868,280199,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
869,280200,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity,Other,17298047.0,
870,280203,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against E6SM cells assessed as alteration in cell morphology,Other,17298047.0,
871,280204,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against HeLa cells assessed as alteration in cell morphology,Other,17298047.0,
872,280205,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against Vero cells assessed as alteration in cell morphology,Other,17298047.0,
873,280206,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against C3H cells assessed as alteration in cell morphology,Other,17298047.0,
874,280941,6,3,,103202903,446727,Unspecified,,,80.75,IC50,Cytotoxicity against mouse L1210/0 cells after 48 hrs,Confirmatory,17341060.0,
875,284525,8,3,,103202903,446727,Active,,,,,Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells,Other,17092728.0,
876,284527,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells,Other,17092728.0,
877,284529,8,1,,103202903,446727,Active,,,,,Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells,Other,17092728.0,
878,284531,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells,Other,17092728.0,
879,284533,8,3,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells,Other,17092728.0,
880,284535,8,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against E6SM cells,Other,17092728.0,
881,284537,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus-induced cytopathogenicity in Vero cells,Other,17092728.0,
882,284538,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4-induced cytopathogenicity in Vero cells,Other,17092728.0,
883,284539,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus-induced cytopathogenicity in Vero cells,Other,17092728.0,
884,284540,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus- induced cytopathogenicity in HeLa cells,Other,17092728.0,
885,286285,6,2,,103202903,446727,Unspecified,,,15.0,IC50,Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay,Confirmatory,17402726.0,
886,286286,6,2,,103202903,446727,Unspecified,,,15.0,IC50,Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC2 cells after 120 hrs by MTT assay,Confirmatory,17402726.0,
887,286287,6,3,,103202903,446727,Unspecified,,,15.0,IC50,Cytotoxicity against DG75 cells after 120 hrs by MTT assay,Confirmatory,17402726.0,
888,288915,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against E6SM cells assessed as alteration in cell morphology,Other,17518459.0,
889,288916,6,4,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
890,288917,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
891,288918,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
892,288919,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
893,288920,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17518459.0,
894,288938,6,2,,103202903,446727,Unspecified,,,250.0,IC50,Inhibition of proliferation of thymidine kinase deficient OST cells,Confirmatory,17518459.0,
895,288939,6,2,,103202903,446727,Active,,,0.6,IC50,Inhibition of proliferation of VZV thymidine kinase expressing OSTtk-/VZVtk+ -a cells,Confirmatory,17518459.0,
896,288940,6,2,,103202903,446727,Active,,,0.35,IC50,Inhibition of proliferation of VZV thymidine kinase expressing OSTtk-/VZVtk+ -b cells,Confirmatory,17518459.0,
897,291029,6,2,,103202903,446727,Active,,,0.013999999999999999,EC50,Antiviral activity against thymidine kinase expressing Varicella-Zoster virus OKA assessed as reduction of plaque formation,Confirmatory,17539622.0,
898,291030,6,2,,103202903,446727,Unspecified,,,168.0,EC50,Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 assessed as reduction of plaque formation,Confirmatory,17539622.0,
899,291031,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as cell morphology after 7 days,Other,17539622.0,
900,291032,6,3,,103202903,446727,Unspecified,,,408.0,CC50,Cytotoxicity against HEL cells assessed as cell growth after 7 days,Confirmatory,17539622.0,
901,291033,6,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
902,291034,6,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
903,291035,6,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
904,291036,6,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
905,291037,6,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17539622.0,
906,296672,6,2,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
907,296673,6,2,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
908,296674,6,2,,103202903,446727,Unspecified,,,99.0,EC50,Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
909,296675,6,2,,103202903,446727,Unspecified,,,130.0,EC50,Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days,Confirmatory,17622128.0,
910,296676,6,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17622128.0,
911,296677,6,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days,Confirmatory,17622128.0,
912,296678,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days,Other,17622128.0,
913,296679,6,3,,103202903,446727,Unspecified,,,150.0,CC50,Cytotoxicity against HEL cells after 3 days,Confirmatory,17622128.0,
914,297306,6,2,,103202903,446727,Active,,,0.013999999999999999,EC50,Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days,Confirmatory,17672445.0,
915,297307,6,2,,103202903,446727,Unspecified,,,168.0,EC50,Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days,Confirmatory,17672445.0,
916,297310,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration in cell morphology,Other,17672445.0,
917,297311,6,3,,103202903,446727,Unspecified,,,270.0,CC50,Cytotoxicity against human HEL cells assessed as reduction of cell growth,Confirmatory,17672445.0,
918,297312,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
919,297313,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Parainfluenza 3 virus in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
920,297314,8,3,,103202903,446727,Active,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
921,297315,8,1,,103202903,446727,Active,,,,,Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
922,297316,8,1,,103202903,446727,Active,,,,,Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
923,297317,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
924,297318,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Reovirus 1 in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
925,297319,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
926,297320,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
927,297321,8,1,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17672445.0,
928,303209,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
929,303210,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
930,303211,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
931,303212,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
932,303213,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VZV OKA in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
933,303214,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VZV 07-1 TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
934,303221,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days,Other,17948980.0,
935,303224,8,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as cell growth after 3 days,Other,17948980.0,
936,303228,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
937,303229,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
938,303230,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
939,303231,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
940,303232,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity,Other,17948980.0,
941,303233,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
942,303234,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
943,303235,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
944,303236,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days,Other,17948980.0,
945,303237,7,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against HeLa cells assessed as alteration in morphology after 3 days,Other,17948980.0,
946,303238,7,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against Vero cells assessed as alteration in morphology after 3 days,Other,17948980.0,
947,304882,6,2,,103202903,446727,Active,,,0.005,EC50,Antiviral activity against TK+ VZV OKA in HEL cells after 5 days,Confirmatory,18052321.0,
948,304883,6,2,,103202903,446727,Active,,,0.005,EC50,Antiviral activity against TK+ VZV YS in HEL cells after 5 days,Confirmatory,18052321.0,
949,304884,6,2,,103202903,446727,Unspecified,,,200.0,EC50,Antiviral activity against TK- VZV 07 in HEL cells after 5 days,Confirmatory,18052321.0,
950,304885,6,2,,103202903,446727,Unspecified,,,200.0,EC50,Antiviral activity against TK- VZV YS in HEL cells after 5 days,Confirmatory,18052321.0,
951,304886,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology,Other,18052321.0,
952,304887,6,3,,103202903,446727,Unspecified,,,200.0,CC50,Cytotoxicity against HEL cells,Confirmatory,18052321.0,
953,304888,6,2,,103202903,446727,Active,,,1.3,IC50,Inhibition of VZV-TK catalyzed dThd phosphorylation,Confirmatory,18052321.0,
954,309810,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation,Other,17869124.0,
955,309811,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK- VZV 07/1 in HEL cells assessed as reduction of virus plaque formation,Other,17869124.0,
956,309812,7,2,,103202903,446727,Inconclusive,,,,,Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days,Other,17869124.0,
957,309813,7,2,,103202903,446727,Inconclusive,,,,,Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days,Other,17869124.0,
958,309814,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology after 3 days,Other,17869124.0,
959,309815,7,3,,103202903,446727,Inconclusive,,,,,Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days,Other,17869124.0,
960,326127,9,2,,103202903,446727,Active,,,32.3,IC50,Inhibition of Herpes B virus recombinant thymidine kinase-mediated [3H]TdR phosphorylation,Confirmatory,17438061.0,
961,326128,10,5,,103202903,446727,Active,59799779.0,,,IC50,Inhibition of Herpes simplex virus 1 recombinant thymidine kinase,Confirmatory,17438061.0,
962,326131,4,7,,103202903,446727,Inactive,,,,,Activity of Herpes B virus recombinant thymidine kinase at 100 uM,Other,17438061.0,
963,326132,3,7,,103202903,446727,Inactive,,,,,Activity of Herpes B virus recombinant thymidine kinase at 1 mM,Other,17438061.0,
964,326134,6,4,,103202903,446727,Unspecified,,,300.0,EC50,Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
965,326135,6,4,,103202903,446727,Unspecified,,,300.0,EC50,Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
966,326136,6,4,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
967,326137,6,2,,103202903,446727,Active,,,0.12,EC50,Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs,Confirmatory,17438061.0,
968,326138,6,2,,103202903,446727,Unspecified,,,600.0,CC50,Cytotoxicity against african green monkey Vero cells after 2 days,Confirmatory,17438061.0,
969,383506,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HeLa cells,Other,17583388.0,
970,383507,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against vesicular stomatitis virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Other,17583388.0,
971,383508,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Other,17583388.0,
972,383509,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against respiratory syncytial virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity,Other,17583388.0,
973,383510,8,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against human E6SM cells,Other,17583388.0,
974,383511,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of cell morphology,Other,17583388.0,
975,383512,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
976,383513,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
977,383514,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
978,383515,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
979,383516,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
980,383517,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
981,383518,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
982,383519,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
983,383520,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
984,383521,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
985,383522,5,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells,Other,17583388.0,
986,383523,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackie virus B4 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
987,383524,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
988,383527,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation,Other,17583388.0,
989,383528,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK- VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation,Other,17583388.0,
990,383530,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Parainfluenza 3 virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
991,383531,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Reo virus 1 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
992,383532,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity,Other,17583388.0,
993,387582,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
994,387602,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
995,387854,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay,Other,18778942.0,
996,388918,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase expressing Varicella-Zoster virus Oka in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
997,388919,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase deficient Varicella-Zoster virus 07/1 in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
998,388920,7,2,,103202903,446727,Inconclusive,,,,,Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
999,388921,7,2,,103202903,446727,Inconclusive,,,,,Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity,Other,18835175.0,
1000,388922,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as morphological alteration after 3 days,Other,18835175.0,
1001,388923,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as reduction of growth after 3 days,Other,18835175.0,
1002,392511,8,1,,103202903,446727,Active,,,48.0,IC50,Antiviral activity against Herpes simplex virus 1,Confirmatory,19112024.0,
1003,392512,8,1,,103202903,446727,Active,,,0.076,IC50,Antiviral activity against Herpes simplex virus 2,Confirmatory,19112024.0,
1004,392515,6,2,,103202903,446727,Unspecified,,,150.0,IC50,Antiviral activity against Human cytomegalovirus,Confirmatory,19112024.0,
1005,392536,6,2,,103202903,446727,Unspecified,,,400.0,IC50,Antiviral activity against Vaccinia virus,Confirmatory,19112024.0,
1006,392537,10,1,,103202903,446727,Active,,,29.0,IC50,Antiviral activity against Varicella zoster virus,Confirmatory,19112024.0,
1007,393979,6,2,,103202903,446727,Active,,,0.015,EC50,Antiviral activity against thymidine kinase expressing Varicella zoster virus Oka infected in human HEL cells assessed reduction in viral plaque formation,Confirmatory,19226140.0,
1008,393980,6,2,,103202903,446727,Unspecified,,,140.0,EC50,Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed reduction in viral plaque formation,Confirmatory,19226140.0,
1009,393981,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as morphological alteration after 3 days,Other,19226140.0,
1010,393982,6,3,,103202903,446727,Unspecified,,,600.0,CC50,Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days,Confirmatory,19226140.0,
1011,416772,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days,Other,19281225.0,
1012,416773,6,2,,103202903,446727,Active,,,0.02,EC50,Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1013,416774,6,2,,103202903,446727,Active,,,29.0,EC50,Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1014,416775,6,2,,103202903,446727,Active,,,4.0,EC50,Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1015,416776,6,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1016,416777,6,2,,103202903,446727,Unspecified,,,50.0,EC50,Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,19281225.0,
1017,419591,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration in cell morphology,Other,18851889.0,
1018,419592,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1019,419593,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1020,419594,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1021,419595,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1022,419596,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days,Other,18851889.0,
1023,429196,6,2,,103202903,446727,Active,,,0.026000000000000002,EC50,Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days,Confirmatory,19339082.0,
1024,429197,6,2,,103202903,446727,Active,,,0.015,EC50,Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days,Confirmatory,19339082.0,
1025,429198,6,2,,103202903,446727,Unspecified,,,157.0,EC50,Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days,Confirmatory,19339082.0,
1026,429201,6,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as microscopically detectable morphological alterations after 3 days,Other,19339082.0,
1027,429202,6,3,,103202903,446727,Unspecified,,,432.0,CC50,Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days,Confirmatory,19339082.0,
1028,432169,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology,Other,19419804.0,
1029,432170,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1030,432171,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1031,432172,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1032,432173,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1033,432176,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days,Other,19419804.0,
1034,434306,7,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as change in cell morphology,Other,19324473.0,
1035,434307,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1036,434308,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity,Other,19324473.0,
1037,434309,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1038,434310,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1039,434311,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1040,434312,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1041,434313,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1042,434314,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against RSV infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1043,434315,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1044,434316,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1045,434317,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1046,434318,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1047,434319,7,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity,Other,19324473.0,
1048,434320,7,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as change in cell morphology,Other,19324473.0,
1049,434321,7,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as change in cell morphology,Other,19324473.0,
1050,463096,1,1,,50105913,446727,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1051,463097,1,1,,50105913,446727,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1052,463189,1,1,,53777281,446727,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1053,463989,5,2,,103202903,446727,Active,,,0.08,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1054,463990,5,2,,103202903,446727,Unspecified,,,50.0,EC50,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1055,463991,5,2,,103202903,446727,Active,,,2.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1056,463992,5,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay,Confirmatory,20034711.0,
1057,463993,5,2,,103202903,446727,Unspecified,,,50.0,EC50,Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay,Confirmatory,20034711.0,
1058,464178,5,3,,103202903,446727,Unspecified,,,250.0,CC50,Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1059,464179,5,3,,103202903,446727,Unspecified,,,250.0,CC50,Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1060,464180,5,3,,103202903,446727,Unspecified,,,250.0,CC50,Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1061,464181,5,3,,103202903,446727,Unspecified,,,250.0,CC50,Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1062,464182,5,3,,103202903,446727,Unspecified,,,250.0,CC50,Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method,Confirmatory,20034711.0,
1063,482702,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1064,482703,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1065,482704,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1066,482705,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1067,482706,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1068,482707,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1069,482708,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1070,482709,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human E6SM cells by MTT assay,Other,20377249.0,
1071,482710,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,20377249.0,
1072,482711,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1073,482712,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1074,482713,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1075,482714,6,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity,Other,20377249.0,
1076,482715,6,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells by MTT assay,Other,20377249.0,
1077,485290,1,1,,50105913,446727,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1078,485314,1,1,,50105913,446727,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1079,488745,1,4,,50105913,446727,Inconclusive,,,13.1154,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1080,488752,1,4,,50105913,446727,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1081,488949,1,2,,50105913,446727,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1082,488979,1,1,,50105913,446727,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1083,488980,1,1,,50105913,446727,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1084,492961,1,1,,50105913,446727,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
1085,493127,1,1,,50105913,446727,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1086,493189,1,1,,50105913,446727,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1087,504327,1,1,,50105913,446727,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1088,504332,1,1,,50105913,446727,Inactive,168985070.0,,0.0251,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1089,504364,1,1,,50105913,446727,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1090,504749,1,3,,50105913,446727,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1091,504749,1,3,1.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1092,504749,1,3,2.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1093,504749,1,3,3.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1094,504749,1,3,4.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1095,504749,1,3,5.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1096,504749,1,3,6.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1097,504749,1,3,7.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1098,504749,1,3,8.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1099,504749,1,3,9.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1100,504749,1,3,10.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1101,504749,1,3,11.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1102,504749,1,3,12.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1103,504749,1,3,13.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1104,504749,1,3,14.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1105,504749,1,3,15.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1106,504749,1,3,16.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1107,504749,1,3,17.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1108,504749,1,3,18.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1109,504749,1,3,19.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1110,504749,1,3,20.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1111,504749,1,3,21.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1112,504749,1,3,22.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1113,504749,1,3,23.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1114,504749,1,3,24.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1115,504749,1,3,25.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1116,504749,1,3,26.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1117,504749,1,3,27.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1118,504749,1,3,28.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1119,504749,1,3,29.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1120,504749,1,3,30.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1121,504749,1,3,31.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1122,504749,1,3,32.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1123,504749,1,3,33.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1124,504749,1,3,34.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1125,504749,1,3,35.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1126,504749,1,3,36.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1127,504749,1,3,37.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1128,504749,1,3,38.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1129,504749,1,3,39.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1130,504749,1,3,40.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1131,504749,1,3,41.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1132,504749,1,3,42.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1133,504749,1,3,43.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1134,504749,1,3,44.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1135,504749,1,3,45.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1136,504749,1,3,46.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1137,504749,1,3,47.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1138,504749,1,3,48.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1139,504749,1,3,49.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1140,504749,1,3,50.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1141,504749,1,3,51.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1142,504749,1,3,52.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1143,504749,1,3,53.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1144,504749,1,3,54.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1145,504749,1,3,55.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1146,504749,1,3,56.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1147,504749,1,3,57.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1148,504749,1,3,58.0,50105913,446727,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1149,504749,1,3,59.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1150,504749,1,3,60.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1151,504749,1,3,61.0,50105913,446727,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1152,504821,1,1,,50105913,446727,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1153,504832,1,1,,50105913,446727,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1154,504834,1,1,,50105913,446727,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1155,504847,1,1,,50105913,446727,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1156,504865,1,1,,50105913,446727,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1157,516962,5,3,,103202903,446727,Unspecified,,,300.0,CC50,Cytotoxicity against HEL assessed as change in cell morphology,Confirmatory,20809641.0,
1158,516964,5,3,,103202903,446727,Unspecified,,,339.0,CC50,Cytotoxicity against HEL,Confirmatory,20809641.0,
1159,516965,4,4,,103202903,446727,Active,,,0.03,EC50,Antiviral activity against HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
1160,516966,4,4,,103202903,446727,Unspecified,,,150.0,EC50,Antiviral activity against acyclovir-resistant HSV1 KOS infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
1161,516967,4,4,,103202903,446727,Unspecified,,,75.3,EC50,Antiviral activity against acyclovir-resistant HSV2 strain G infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
1162,516968,4,2,,103202903,446727,Active,,,0.016,EC50,Antiviral activity against acyclovir-resistant VZV OKA infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
1163,516969,4,2,,103202903,446727,Unspecified,,,137.0,EC50,Antiviral activity against acyclovir-resistant VZV 07/1 infected in HEL assessed as reduction in virus-induce cytopathicity,Confirmatory,20809641.0,
1164,521220,3,3,,103202903,446727,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1165,539914,3,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days,Other,20724039.0,
1166,539915,5,4,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
1167,539916,5,4,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
1168,539917,4,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
1169,539918,4,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
1170,539919,5,4,,103202903,446727,Unspecified,,,,,Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days,Other,20724039.0,
1171,540256,1,2,,50105913,446727,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1172,540276,1,2,,50105913,446727,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1173,540276,1,2,,50105914,446727,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1174,548423,4,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as altered cell morphology,Other,20971531.0,
1175,548424,5,4,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
1176,548425,5,4,,103202903,446727,Unspecified,,,,,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
1177,548426,4,3,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
1178,548427,4,3,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
1179,548428,5,4,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay,Other,20971531.0,
1180,553336,5,3,,103202903,446727,Unspecified,,,,CC50,Cytotoxicity against human HEL cells after 3 days,Confirmatory,21128666.0,
1181,553337,4,4,,103202903,446727,Active,,,0.04,EC50,Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
1182,553338,4,4,,103202903,446727,Active,,,30.0,EC50,Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
1183,553339,4,4,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
1184,553340,4,2,,103202903,446727,Active,,,1.5,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
1185,553341,4,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days,Confirmatory,21128666.0,
1186,553342,4,2,,103202903,446727,Active,,,0.012,EC50,Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days,Confirmatory,21128666.0,
1187,553343,4,2,,103202903,446727,Unspecified,,,100.0,EC50,Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days,Confirmatory,21128666.0,
1188,567091,2,6,,103202903,446727,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
1189,569231,4,4,,103202903,446727,Active,,,0.02,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
1190,569232,4,4,,103202903,446727,Active,,,6.0,EC50,Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
1191,569233,4,4,,103202903,446727,Unspecified,,,180.0,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
1192,569234,4,2,,103202903,446727,Active,,,0.003,EC50,Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of plaque formation,Confirmatory,21232828.0,
1193,569235,4,2,,103202903,446727,Unspecified,,,54.4,EC50,Antiviral activity against VZV 07-1 infected in HEL cells assessed as inhibition of plaque formation,Confirmatory,21232828.0,
1194,569238,4,2,,103202903,446727,Active,,,2.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21232828.0,
1195,569239,5,3,,103202903,446727,Unspecified,,,,CC50,Cytotoxicity against HEL cells after 3 days by coulter counter analysis,Confirmatory,21232828.0,
1196,588453,1,1,,50105913,446727,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1197,588579,1,1,,50105913,446727,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1198,588590,1,1,,50105913,446727,Inconclusive,154350220.0,11201.0,14.1254,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1199,588591,1,1,,50105913,446727,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1200,588834,2,1,,144204764,446727,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1201,602332,1,1,,50105913,446727,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1202,607906,3,4,,103202903,446727,Active,,,0.08,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
1203,607907,3,4,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
1204,607908,3,2,,103202903,446727,Active,,,30.0,EC50,Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
1205,607909,3,4,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
1206,607910,3,2,,103202903,446727,Active,,,10.0,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis,Confirmatory,21696963.0,
1207,607911,3,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of normal cell morphology by microscopic analysis,Other,21696963.0,
1208,607912,3,3,,103202903,446727,Unspecified,,,100.0,CC50,Cytotoxicity against cat CRFK cells by colorimetric formazan-based MTS assay,Confirmatory,21696963.0,
1209,607913,3,2,,103202903,446727,Active,,,0.011000000000000001,EC50,Antiviral activity against Varicella-zoster virus YS expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation,Confirmatory,21696963.0,
1210,607914,3,2,,103202903,446727,Active,,,0.03,EC50,Antiviral activity against Varicella-zoster virus OKA expressing thymidine kinase infected in human HEL cells assessed as reduction in the virus plaque formation,Confirmatory,21696963.0,
1211,607915,3,2,,103202903,446727,Unspecified,,,60.0,EC50,Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation,Confirmatory,21696963.0,
1212,607916,3,2,,103202903,446727,Unspecified,,,150.0,EC50,Antiviral activity against thymidine kinase-deficient Varicella-zoster virus YS/R infected in human HEL cells assessed as reduction in the virus plaque formation,Confirmatory,21696963.0,
1213,607919,3,3,,103202903,446727,Unspecified,,,512.0,CC50,Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay,Confirmatory,21696963.0,
1214,611615,3,4,,103202903,446727,Active,,,0.027999999999999997,EC50,Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1215,611616,3,4,,103202903,446727,Unspecified,,,274.3,EC50,Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1216,611617,3,4,,103202903,446727,Active,,,45.7,EC50,Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1217,611618,3,2,,103202903,446727,Active,,,0.013000000000000001,EC50,Antiviral activity against VZV OKA infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1218,611619,3,2,,103202903,446727,Unspecified,,,105.4,EC50,Antiviral activity against VZV 07/1 infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1219,611620,3,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1220,611621,3,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1221,611622,3,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1222,611623,3,2,,103202903,446727,Active,,,4.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity,Confirmatory,21565516.0,
1223,611624,3,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as alteration of cell morphology after 3 days by microscopy,Other,21565516.0,
1224,611625,3,3,,103202903,446727,Unspecified,,,470.0,CC50,Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter,Confirmatory,21565516.0,
1225,611626,3,3,,103202903,446727,Inconclusive,,,,CC50,Cytotoxicity against cat CRFK cells assessed as growth inhibition after 3 days by coulter counter,Confirmatory,21565516.0,
1226,624030,1,2,,50105913,446727,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1227,624031,1,2,,50105913,446727,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1228,624032,1,2,,50105913,446727,Inactive,8393992.0,24660.0,0.5103,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1229,624044,1,2,,50105913,446727,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1230,624170,1,1,,50105913,446727,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1231,624172,1,1,,50105913,446727,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1232,624173,1,3,,50105913,446727,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1233,624296,1,1,,50105913,446727,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1234,624297,1,1,,50105913,446727,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1235,634746,1,6,,103202903,446727,Inactive,,,,,Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1236,634747,1,6,,103202903,446727,Inactive,,,,,Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1237,634748,1,6,,103202903,446727,Inactive,,,,,Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1238,634749,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1239,634750,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1240,634751,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1241,634752,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1242,634753,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1243,634754,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1244,634755,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1245,634756,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1246,634757,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1247,634758,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1248,634759,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1249,634760,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1250,634761,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1251,634831,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1252,634832,1,5,,103202903,446727,Inactive,,,,,Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1253,634833,1,5,,103202903,446727,Inactive,,,,,Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1254,634834,1,5,,103202903,446727,Inactive,,,,,Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1255,634835,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1256,634836,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM,Other,22137458.0,
1257,634837,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Other,22137458.0,
1258,634838,1,4,,103202903,446727,Inactive,,,,,Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis,Other,22137458.0,
1259,651631,4,1,,144204764,446727,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1260,651632,4,1,,144204764,446727,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1261,651633,4,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1262,651634,4,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1263,652048,1,2,,144204764,446727,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1264,652051,1,1,,144204764,446727,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1265,658617,2,4,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
1266,658618,2,4,,103202903,446727,Unspecified,,,50.0,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
1267,658619,2,2,,103202903,446727,Active,,,10.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
1268,658739,2,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
1269,658740,2,4,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days,Confirmatory,22459876.0,
1270,658741,2,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology,Other,22459876.0,
1271,658754,2,2,,103202903,446727,Unspecified,,,362.0,CC50,Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay,Confirmatory,22459876.0,
1272,658755,2,2,,103202903,446727,Active,,,0.019,EC50,Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days,Confirmatory,22459876.0,
1273,658756,2,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days,Confirmatory,22459876.0,
1274,665383,2,2,,103202903,446727,Active,,,0.0075,EC50,Antiviral activity against thymidine kinase-positive Varicella-zoster virus YS infected in HEL cells assessed as reduction in virus-induced cytopathicity,Confirmatory,22578783.0,
1275,665384,2,2,,103202903,446727,Active,,,0.0087,EC50,Antiviral activity against thymidine kinase-positive Varicella-zoster virus OKA infected in HEL cells assessed as reduction in virus-induced cytopathicity,Confirmatory,22578783.0,
1276,665385,2,2,,103202903,446727,Unspecified,,,74.0,EC50,Antiviral activity against thymidine kinase-deficient Varicella-zoster virus 07/1 infected in HEL cells assessed as reduction in virus-induced cytopathicity,Confirmatory,22578783.0,
1277,665388,2,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as change in cell morphology by microscopic analysis,Other,22578783.0,
1278,665389,2,3,,103202903,446727,Unspecified,,,100.0,CC50,Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter,Confirmatory,22578783.0,
1279,675210,2,2,,103202903,446727,Active,,,0.006,EC50,Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
1280,675211,2,2,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
1281,675212,2,2,,103202903,446727,Unspecified,,,53.0,EC50,Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
1282,675213,2,2,,103202903,446727,Unspecified,,,120.0,EC50,Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay,Confirmatory,22858222.0,
1283,675214,2,2,,103202903,446727,Active,,,0.038,EC50,Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
1284,675215,2,4,,103202903,446727,Unspecified,,,105.0,EC50,Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
1285,675216,2,2,,103202903,446727,Unspecified,,,183.0,EC50,Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
1286,675217,2,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
1287,675218,2,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
1288,675219,2,2,,103202903,446727,Inconclusive,,,,EC50,Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay,Confirmatory,22858222.0,
1289,675220,2,2,,103202903,446727,Active,,,15.0,EC50,Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay,Confirmatory,22858222.0,
1290,675221,2,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as effect on cell morphology incubated for 3 days by microscopy,Other,22858222.0,
1291,675222,2,3,,103202903,446727,Unspecified,,,347.0,CC50,Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay,Confirmatory,22858222.0,
1292,686978,1,1,,144204764,446727,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1293,686979,1,1,,144204764,446727,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1294,687035,1,1,,163564129,446727,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
1295,687037,1,3,,163564129,446727,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
1296,687660,2,2,,103202903,446727,Active,,,5.0,EC50,Antiviral activity against Vaccinia virus infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days,Confirmatory,23047229.0,
1297,687661,2,4,,103202903,446727,Active,,,0.08,EC50,Antiviral activity against HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days,Confirmatory,23047229.0,
1298,687662,2,4,,103202903,446727,Unspecified,,,50.0,EC50,Antiviral activity against HSV2 G infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days,Confirmatory,23047229.0,
1299,687663,2,4,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in HEL assessed as inhibition of virus-induced cytopathicity after 3 days,Confirmatory,23047229.0,
1300,687664,2,2,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days,Confirmatory,23047229.0,
1301,687665,2,2,,103202903,446727,Unspecified,,,117.0,EC50,Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days,Confirmatory,23047229.0,
1302,687666,2,3,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL assessed as minimum compound concentration causes microscopically detectable alteration of cell morphology after 3 days,Other,23047229.0,
1303,687667,2,3,,103202903,446727,Unspecified,,,339.0,CC50,Cytotoxicity against HEL after 3 days,Confirmatory,23047229.0,
1304,718733,2,3,,103202903,446727,Unspecified,,,,,Toxicity in HEL cells assessed as induction of cell morphology changes,Other,23099097.0,
1305,718734,2,4,,103202903,446727,Unspecified,,,50.0,EC50,Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
1306,718735,2,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
1307,718736,2,2,,103202903,446727,Active,,,10.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
1308,718737,2,4,,103202903,446727,Unspecified,,,198.0,EC50,Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
1309,718738,2,4,,103202903,446727,Active,,,0.024,EC50,Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,23099097.0,
1310,720516,2,1,,144204764,446727,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1311,720532,1,1,,144204764,446727,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1312,720533,1,1,,144204764,446727,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1313,720552,2,1,,144204764,446727,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1314,720634,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1315,720635,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1316,720637,2,1,,144204764,446727,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1317,720674,2,2,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1318,720675,2,2,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1319,720678,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1320,720679,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1321,720680,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1322,720681,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1323,720682,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1324,720683,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1325,720684,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1326,720685,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1327,720686,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1328,720687,2,2,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1329,720691,4,1,,144204764,446727,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1330,720692,3,1,,144204764,446727,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1331,720693,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1332,720719,2,1,,144204764,446727,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1333,720725,2,1,,144204764,446727,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1334,743012,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1335,743014,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1336,743015,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1337,743033,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1338,743035,2,1,,144204764,446727,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1339,743036,2,1,,144204764,446727,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1340,743040,3,1,,144204764,446727,Inconclusive,124375976.0,367.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1341,743041,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1342,743042,3,1,,144204764,446727,Inactive,124375976.0,367.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1343,743053,2,1,,144204764,446727,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1344,743054,2,1,,144204764,446727,Inconclusive,124375976.0,367.0,19.9496,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1345,743063,2,1,,144204764,446727,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1346,743064,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1347,743065,3,1,,144204764,446727,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1348,743066,3,1,,144204764,446727,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1349,743067,2,1,,144204764,446727,Inconclusive,399498506.0,24831.0,11.8832,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1350,743069,2,1,,144204764,446727,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1351,743074,2,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1352,743075,2,1,,144204764,446727,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1353,743077,2,1,,144204764,446727,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1354,743078,2,1,,144204764,446727,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1355,743079,3,1,,144204764,446727,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1356,743080,3,1,,144204764,446727,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1357,743081,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1358,743083,3,1,,144204764,446727,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1359,743084,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1360,743085,3,1,,144204764,446727,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1361,743086,3,1,,144204764,446727,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1362,743091,2,1,,144204764,446727,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1363,743094,3,1,,144204764,446727,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1364,743122,2,1,,144204764,446727,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1365,743139,2,1,,144204764,446727,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1366,743140,2,1,,144204764,446727,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1367,743244,1,1,,144204764,446727,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1368,766696,1,3,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against thymidine kinase negative acyclovir positive Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
1369,766697,1,1,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
1370,766698,1,1,,103202903,446727,Active,,,10.0,EC50,Antiviral activity against Vaccinia virus Lederle infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
1371,766699,1,3,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
1372,766700,1,3,,103202903,446727,Active,,,0.4,EC50,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity,Confirmatory,23911856.0,
1373,766703,1,1,,103202903,446727,Active,,,33.0,EC50,Antiviral activity against thymidine kinase negative Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction in the virus plaque formation,Confirmatory,23911856.0,
1374,766704,1,1,,103202903,446727,Active,,,0.02,EC50,Antiviral activity against thymidine kinase positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction in virus plaque formation,Confirmatory,23911856.0,
1375,766711,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells assessed as morphological changes,Other,23911856.0,
1376,768200,1,3,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
1377,768201,1,1,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
1378,768202,1,1,,103202903,446727,Active,,,5.0,EC50,Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
1379,768203,1,3,,103202903,446727,Unspecified,,,146.0,EC50,Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
1380,768204,1,3,,103202903,446727,Active,,,0.04,EC50,Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,23811093.0,
1381,768205,1,1,,103202903,446727,Unspecified,,,144.9,EC50,Antiviral activity against TK-positive Varicella-zoster virus 07-1 infected in human HEL cells assessed as reduction of plaque formation,Confirmatory,23811093.0,
1382,768206,1,1,,103202903,446727,Active,,,3.82,EC50,Antiviral activity against TK-positive Varicella-zoster virus OKA infected in human HEL cells assessed as reduction of plaque formation,Confirmatory,23811093.0,
1383,768207,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against human HEL cells,Other,23811093.0,
1384,1095321,3,1,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
1385,1095322,3,1,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
1386,1095323,3,1,,103202903,446727,Active,,,10.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
1387,1095324,3,1,,103202903,446727,Unspecified,,,126.0,EC50,Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
1388,1095325,3,1,,103202903,446727,Active,,,0.08,EC50,Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay,Confirmatory,,
1389,1095326,3,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells after 3 days by microscopic analysis,Other,,
1390,1097055,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL assessed as minimum concentration required to cause morphological changes,Other,,
1391,1097058,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL,Other,,
1392,1097059,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase-deficient Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation,Other,,
1393,1097060,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against thymidine kinase-positive Human herpesvirus 3 infected in HEL cells assessed as inhibition of viral plaque formation,Other,,
1394,1106648,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Respiratory syncytial virus infected HeLa cells,Other,,
1395,1106649,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Human coxsackievirus B4 infected HeLa cells,Other,,
1396,1106650,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected HeLa,Other,,
1397,1106651,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Human coxsackievirus B4 infected Vero cells,Other,,
1398,1106652,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Punta Toro virus infected Vero cells,Other,,
1399,1106653,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Sindbis virus infected Vero cells,Other,,
1400,1106654,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells,Other,,
1401,1106655,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Human parainfluenza virus 3 infected Vero cells,Other,,
1402,1106656,1,2,,103202903,446727,Unspecified,,,,,"Antiviral activity against thymidine kinase-deficient, acylcovir-resistant Human herpesvirus 1 strain KOS infected in HEL cells",Other,,
1403,1106657,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vesicular stomatitis virus infected HEL cells,Other,,
1404,1106658,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Vaccinia virus infected HEL cells,Other,,
1405,1106659,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Human herpesvirus 2 strain G infected HEL cells,Other,,
1406,1106660,1,2,,103202903,446727,Unspecified,,,,,Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells,Other,,
1407,1106661,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa cells,Other,,
1408,1106662,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells,Other,,
1409,1106663,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells,Other,,
1410,1113466,1,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
1411,1113467,1,2,,103202903,446727,Unspecified,,,250.0,EC50,Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
1412,1113468,1,2,,103202903,446727,Active,,,29.0,EC50,Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
1413,1113469,1,2,,103202903,446727,Unspecified,,,150.0,EC50,Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
1414,1113470,1,2,,103202903,446727,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HEL cells assessed as change in cellular morphology,Other,,
1415,1113471,1,2,,103202903,446727,Active,,,0.08,EC50,Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay,Confirmatory,,
1416,1159580,2,1,,268737893,446727,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1417,1159607,2,1,,313041386,446727,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1418,1159620,1,1,,103202903,446727,Active,,,,,Summary of drug indications.,Other,,
1419,1230099,1,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis,Other,26001344.0,
1420,1230100,1,1,,103202903,446727,Active,,,0.028999999999999998,EC50,Antiviral activity against Varicella-zoster virus expressing thymidine kinase infected in HEL cells assessed as reduction of virus-induced plaque formation,Confirmatory,26001344.0,
1421,1230101,1,1,,103202903,446727,Active,,,1.0,EC50,Antiviral activity against thymidine kinase-deficient Varicella-zoster virus infected in HEL cells assessed as reduction of virus-induced plaque formation,Confirmatory,26001344.0,
1422,1230102,1,1,,103202903,446727,Active,,,0.01,EC50,Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
1423,1230103,1,1,,103202903,446727,Active,,,2.0,EC50,Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
1424,1230104,1,1,,103202903,446727,Unspecified,,,146.0,EC50,Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
1425,1230105,1,1,,103202903,446727,Active,,,17.0,EC50,Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity,Confirmatory,26001344.0,
1426,1251995,1,1,,103202903,446727,Active,,,0.028999999999999998,EC50,Antiviral activity against thymidine kinase-deficient Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation,Confirmatory,26443550.0,
1427,1251996,1,1,,103202903,446727,Active,,,38.6,EC50,Antiviral activity against thymidine kinase-positive Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation,Confirmatory,26443550.0,
1428,1251997,1,1,,103202903,446727,Unspecified,,,,,Cytotoxicity against Varicella zoster virus infected HEL cells assessed as alteration of cell morphology incubated for 3 days by microscopy,Other,26443550.0,
1429,1251998,1,1,,103202903,446727,Unspecified,,,79.3,CC50,Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method,Confirmatory,26443550.0,
1430,1259310,1,1,,321942222,446727,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1431,1259344,1,1,,144204764,446727,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1432,1259354,1,1,,348414154,446727,Inconclusive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
1433,1259355,1,1,,144204764,446727,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1434,1259356,1,1,,144204764,446727,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1435,1259407,1,1,,363900781,446727,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1436,1259408,1,1,,363897818,446727,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1437,1259423,1,2,,354823735,446727,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
